Nicotine dependence (ND), a major public health challenge, is a complex, multifactorial behavior, in which both genetic and environmental factors have a role. Brain nicotinic acetylcholine receptor (nAChR)-encoding genes are among the most prominent candidate genes studied in the context of ND, because of their biological relevance as binding sites for nicotine. Until recently, most research on the role of nAChRs in ND has focused on two of these genes (encoding the a4-and b2-subunits) and not much attention has been paid to the possible contribution of the other nine brain nAChR subunit genes (a2-a3, a5-a7, a9-a10, b3-b4) to the pathophysiology and genetics of ND. This situation has changed dramatically in the last 2 years during which intensive research had addressed the issue, mainly from the genetics perspective, and has shown the importance of the CHRNA5-CHRNA3-CHRNB4 and CHRNA6-CHRNB3 loci in ND-related phenotypes. In this review, we highlight recent findings regarding the contribution of non-a4/b2-subunit containing nAChRs to ND, based on several lines of evidence: (1) human genetics studies (including linkage analysis, candidate-gene association studies and whole-genome association studies) of several ND-related phenotypes; (2) differential pharmacological and biochemical properties of receptors containing these subunits; (3) evidence from genetically manipulated mice; and (4) the contribution of nAChR genes to ND-related personality traits and neurocognitive profiles. Combining neurobiological genetic and behavioral perspectives, we suggest that genetic susceptibility to ND is not linked to one or two specific nAChR subtype genes but to several. In particular, the a3, a5-6 and b3-4 nAChR subunit-encoding genes may play a much more pivotal role in the neurobiology and genetics of ND than was appreciated earlier. At the functional level, variants in these subunit genes (most likely regulatory) may have independent as well as interactive contributions to the ND phenotype spectrum. We address methodological challenges in the field, highlight open questions and suggest possible pathways for future research.
Introduction
Tobacco addiction is a major public health challenge. Cigarette smoking is the leading cause of preventable death in the United States (around 440 000 premature deaths annually during 1997-2001), mostly because of cancer, cardiovascular diseases and respiratory diseases. 1, 2 Globally, it is assumed that tobaccorelated diseases currently kill 4.2 million people per year worldwide. 3 Despite increasing awareness of the severe consequences of smoking, an estimated 45.3 million adults in the United States were current smokers in 2006. 4 Cigarette smoking declined in the United States from 24.7% in 1997 to 20 .8% in 2006, and is declining in most developed countries but remains common in the developing world. 4, 5 Healthrelated economic losses because of smoking were estimated to be $167 billion a year during the period 1997-2001. 1 Although cigarette smoke contains more than 4000 ingredients, 6, 7 the pharmacological effects of tobacco addiction are produced by nicotine. 8 Nicotine reaches the brain in 10-60 s, with an initial concentration of 100-500 nM (depending on how the cigarette is smoked) and binds to nicotinic acetylcholine receptors (nAChRs). 9 Nicotine is extensively metabolized (mainly by the liver), but its average elimination halftime of 2 h, allows nicotine to accumulate in the body of the ongoing smoker for hours. 2, 10 As nicotine reaches the brain so rapidly after a puff, cigarettes are an ideal drug delivery system, enabling smokers to titrate brain nicotine levels with each episode of smoking. 8, 9 Nicotine dependence (ND) is a complex, multifactorial behavior with genetic and environmental underpinnings. 11 The evidence for a significant role of genetic factors in ND and other smoking-related phenotypes is substantial. Heritability estimates for smoking in twin studies range from 46 to 84%. 11 Sullivan and Kendler 12 estimated the heritability of smoking initiation (SI) to be 0.56, with the remaining variance from shared environmental (0.24) and unique environmental effects (0.2). The data for smoking persistence or ND are 0.67, 0.02 and 0.31, respectively. 12 Taking gender into account in a metaanalysis, Li et al. 13 estimated the mean heritability of smoking persistence to be 0.59 in male adults and 0.46 in female adults; shared environmental effects as 0.08 in males and 0.28 in females; and unique environmental effects as 0.37 in males and 0.24 in females. 13 Different approaches to understanding the genetic contribution to ND have been used by researchers worldwide. These include population genetic studies (linkage, candidate-gene and whole-genome association studies), pharmacological and molecular biology approaches, neuroimaging studies and behavioral tests performed on genetically manipulated mice. Genes postulated to be related to smoking behavior phenotypes are implicated in nicotine metabolism (for example, CYP2A6 or CYP2D6) or encode elements of the dopaminergic system (such as the dopamine transporter and the dopamine D2 receptor), serotonin receptors, nAChRs 11, 14 and other candidate genes involved in cell adhesion, signal transduction and transport. 15 A large body of research has sought to link tobacco addiction to one or more specific nAChR subunits. 16 This research has traditionally focused on a4b2-subunit containing nAChRs, based on their high affinity for nicotine, widespread distribution in the brain and the encouraging success of varenicline, a partial agonist of this receptor, as a new smoking cessation therapy. 17 Less attention has been paid to the role of other nAChR receptor subunits in NDrelated phenotypes (See review by Rose 16 ). Recently, whole-genome association studies using highthroughput techniques have found a plethora of genetic variants located in or near nAChR subunitencoding genes to be associated with ND-related phenotypes. In fact, variants in almost all the 11 nAChR subunit-encoding genes have been reported to be associated with some aspect of smoking behavior, at different levels of statistical significance. At first glance, this flood of genetic findings may seem difficult to integrate with current concepts of ND neurobiology and pharmacology; however, we believe that the recent discoveries from several different research disciplines are actually complementary and support each other. They highlight the involvement of genetic variants in different nAChR subunits, assembled into a variety of receptors subtypes, in different ND-related phenotypes and move the field away from a more limited focus on the widespread, high-affinity a4b2-containing receptor.
In this paper, we review the evidence supporting the role of non-a4-and b2-nAChR subunits in ND-related phenotypes. On the basis of recent population genetic and pharmacological studies and genetically manipulated animal models, it appears that non-a4 and b2-nAChRs are substantially involved in the pathophysiology of this complex trait, and variants within them are important risk or protection factors for ND phenotypes. A focus on a4b2-subunit containing receptors cannot explain the multiple facets of human ND behavior such as positive and negative reinforcement, withdrawal, tolerance, subjective response to nicotine and smoking cessation treatment failure. Some of these many facets are probably mediated by additional nAChR subunits and receptor subtypes containing them; genetic variants that influence their function could plausibly be implicated in different ND phenotypes.
Neuronal nAChRs nAChR subunits
Neuronal nAChRs are pentameric, ligand-gated ion channels composed of five membrane-spanning subunits arranged around a central pore that forms a cation channel. [18] [19] [20] In contrast to nicotinic neuromuscular junction receptors, which are composed of a1-, b1-, g-, d-and e-subunits, neuronal nAChRs are composed of a-or b-subunit only. They may be heteropentamers composed of combinations of a-and b-subunits in different ratios or homopentamers of asubunits. Each subunit is encoded by a single gene, nine alpha (a2-a10) and 3 beta (b2-b4), which is expressed in neuronal (central and peripheral nervous system) and non-neuronal tissues. The a8-subunit identified in the avian brain has not been identified in mammals. 21, 22 The 11 nAChR subunit-encoding genes are located on chromosomes 1, 4, 8, 11, 15 and 20 , as shown in Table 1 . CHRNA5, CHRNA3 and CHRNB4 are grouped in a gene cluster on chromosome 15q24. Human CHRNA5 and CHRNA3 are positioned in a tail-to-tail configuration on opposite DNA strands, and share some of their 3 0 UTR. 23 CHRNB3 and CHRNA6 are also grouped in a gene cluster, located on 8p11. The clustered arrangement of CHRNA3/CHRNA5/ CHRNB4 and CHRNB3/CHRNA6 could be related to control of the expression of these genes. Interestingly, the human a7-nAChR gene was found to be partially duplicated, with both loci mapping to the chromosome 15q13 region.
Pharmacological properties of neuronal nAChRs and their involvement in human disorders
Two main classes of neuronal nAChRs are known: a-bungarotoxin (aBgtx)-sensitive receptors are composed of a7-a10-subunits and can form homomeric (such as a7) or heteromeric receptors. aBgtx-insensitive receptors, are heteromeric receptors, consist of a2-a6 and b2-b4-subunits and bind nicotine and other agonists but not aBgtx (such as a4b2* and a3b4* receptors, the * indicating that other, as yet unidentified subunits may also be incorporated in the receptor structure). 22, 25, 26 The different subunit compositions and stoichiometry of each receptor type is responsible for its unique electrophysiological and pharmacological properties. Binding affinity for nicotine differs between receptors, ranging from 'low' to 'high affinity. ' The predominant nAChR in the human brain, a4b2*, has high affinity for nicotine, but differences in the a4/b2-subunits ratio can lead to subtypes with different pharmacological and functional properties. 19, 26 The brain nAChRs are activated by endogenous (acetylcholine) and exogenous ligands (nicotine).
Homopentameric receptors have five identical acetylcholine-binding sites in each molecule, whereas the heteropentameric receptors have only two. Two a-subunits (a2-a4 or a6) carry the principal component of the acetylcholine-binding site, and two non-a-subunits (b2 or b4) carry the binding site complementary component. The fifth subunit does not participate in acetylcholine binding (a5, b3 but also b2 or b4). 25, 27 Each subunit protein has four transmembrane segments, a long extracellular Nterminal domain, an intracellular loop between transmembranes 3 and 4 and a short C-terminal domain.
28 a5-and b3-subunits do not play a direct role in receptor-ligand binding, and function only as auxiliary subunits when expressed with other a-and b-subunits, forming neuronal nAChRs with stoichiometries such as (a4b2) 2 a5 or (a4b2) 2 b3. 27, 29, 30 These subunits may contribute to receptor targeting and localization in the neuronal membrane. [30] [31] [32] Functionally, the nAChR can exist in three conformational states, which are dynamically regulated by agonist exposure: closed, open and desensitized. 33 After nicotine binds to the closed, nonconducting receptor, it becomes activated (open state). Following this, the receptor channel conformation becomes closed, and the receptor is desensitized. Recovery from desensitization takes place only after the nicotine molecule dissociates from the receptor and the activation-desensitization cycle can then restart. Importantly, the receptors are highly sensitive to modulation by many molecules, including divalent cations, steroids, protein kinases and more. 19, 22, 34 The brain nAChRs change considerably during the development and aging in all species 22, 25 and are involved in the pathophysiology of several central nervous system (CNS) diseases other than nicotine addiction. Mutations in the channel region of a4-or b2-subunits have been described in families suffering from autosomal dominant frontal lobe epilepsy, 22 and rare microdeletions of the 15q13.3 segment, which includes the CHRNA7 gene, were reported recently in idiopathic generalized epilepsy. 35 A decrease in the density of nAChRs has been reported in brain disorders such as schizophrenia (in the hippocampus, thalamus and some cortical areas) 36 and Alzheimer's disease (mainly in cortical areas and thalamus), 37 whereas an increase has been reported in the cerebellar cortex and thalamus in autism. 38 Decreased striatal a6b3-receptors have been reported in Parkinson's disease. 39 a7-nAChRs may have a role in cognitive deficits in schizophrenia; in a small trial the a7-nicotinic agonist, anabaseine, appeared to have positive effects on neurocognition in patients with schizophrenia. 40 The use of nicotinic agonists or antagonists in these and other CNS disorders is under intense research. The neurobiology of ND The neurobiology of dependence on nicotine and other drugs of abuse is related to the brain limbic system. 41 A shared property of many addictive drugs, including nicotine, is that they increase dopamine (DA) concentration in the nucleus accumbens (NAc). 42 The mesolimbic DA pathway, which includes dopaminergic neurons in the midbrain ventral tegmental area (VTA) and their target areas in the limbic forebrain, particularly the NAc, is the focus of much research in the field of addiction neurobiology. 41 It seems that the VTA-NAc pathway is critical in drug-induced rewards. 2 Modulation of DA transmission in the VTA-NAc pathway by nicotine is complex, and mediated by nAChRs expressed on several neuronal sub-populations. According to a simplified model, nicotine activates VTA DA neurons and increases their firing rate directly by stimulation of nAChRs expressed on them and indirectly by stimulation of other nAChR receptors on glutamatergic nerve terminals arising from the prefrontal cortex, as well as from the pedunculopontine tegmentum and the laterodorsal tegmentum. 41 These glutamatergic terminals, mainly express a7-containing receptors (a7*), innervate midbrain DA neurons, and activate them. As a result, a similar state to long-term potentiation is induced in the excitatory glutamatergic input to the VTA DA neurons. 9, 42 On the other hand, inhibitory GABAergic interneurons located in the VTA decrease DA neuron activity. They are excited by cholinergic inputs from other parts of the brain. 33, 42 A solid background of experimental literature emphasizes the role of the mesolimbic DA system in nicotine addiction, including attenuation of the rewarding benefit of nicotine in animal models, after blocking DA release in the NAc with antagonists or lesions. 9 The nAChRs on DA VTA neurons (as well as on GABAergic interneurons) are mainly composed of high-affinity a4-and b2-subunits, in combination with other nAChR subunits (a4b2* receptors). 43, 44 The DA VTA and GABAergic interneuron a4b2* receptors desensitize after few minutes of acute nicotine administration (to be discussed later). As a consequence, GABAergic inhibitory input onto DA receptors is decreased. 42 However, in the context of chronic nicotine administration and addiction, great importance is attached to other receptor types with relatively low affinity for nicotine, such as the presynaptic a7*, expressed on the glutamatergic projection to the VTA. These receptors do not strongly desensitize at nicotine levels achieved by smokers and glutamatergic afferent excitation onto DA neurons is enhanced. In parallel, while nicotine level elevates during prolonged smoking, GABAergic neuron a4b2* receptors are desensitized and GABAergic inhibition of dopaminergic neurons in the VTA is effectively depressed. 9, 16 In addition to these mechanisms, the balance of VTA DA excitation/inhibition is fine-tuned by other neurotransmitters, such as serotonin or norepinephrine. 42 Other studies suggest that additional brain regions and pathways are important in ND, including the thalamus, insula, habenula and cortical areas. Some of these areas contain a high density of nAChR. 16, 45 Localization pattern of neuronal nAChRs genes Nicotinic acetylcholine receptors are expressed in both the central (CNS) and peripheral (PNS) nervous systems. 34. nAChRs are extensively expressed throughout the CNS (cortex, hippocampus, striatum, amygdala, thalamus, VTA, substantia nigra, cerebellum, medial habenula, locus coeruleus, olfactory bulb, interpeduncular nucleus (IPN) and pineal gland), 18 allowing nicotine to influence cellular events in many brain regions. The location of nAChRs may be presynaptic, postsynaptic or extrasynaptic but most attention has been given to their presynaptic role. 46 Located presynaptically at cholinergic or non-cholinergic terminals, nAChRs modulate several neurotransmission pathways, such as the cholinergic, dopaminergic, GABAergic, serotonergic pathways and others. 21 As presynaptic receptors, nAChRs modulate exocytosis and neurotransmitter release either by activation of voltage-operated calcium channels following membrane depolarization, or directly because of calcium influx through the receptor pore, altering the intracellular calcium concentration. 19 The a4b2* receptors (the predominant receptor subtype in the brain of humans and other mammalian species) and homomeric a7-receptors are widely expressed within the CNS, 47 while the expression pattern of other subunits is much more restricted to particular brain regions.
18,25,20 a3b4* is the major receptor in the autonomic nervous system and adrenal medulla. 26 However, it is important to note that the same neuronal population may express multiple subtypes of nAChRs.
31 a4b2* receptors may coassemble with additional units, to form more complex receptors such as a4b2a3, a4b2a6 or a4b2a5.
18,48 a7 receptors are also widely expressed in the brain, including VTA, the prefrontal and motor cortex, basal ganglia, hippocampus, cerebellum, and lateral and medial geniculate bodies but with lower expression in the thalamus. 49 There is some evidence that a7-subunits can co-assemble with b-subunits in heterologous systems, but no biochemical evidence of such receptors has been found in neurons. 26, 50 In contrast to a4b2* and a7-receptors, other neuronal nAChRs subunits show a much more restricted localization pattern and are concentrated in specific brain areas. 18 In relation to ND and the focus of this review, the fact that adult midbrain neurons express a variety of nAChR subunit mRNAs, including a3-a7, b2 and b3, is of particular importance. These results have been confirmed (with relatively small discrepancies) by several independent studies of nAChR subunit mRNA expression in the midbrain DA and non-DA neurons. 43, 44, 51, 52 Owing to the biological importance of this area in drug dependence, these receptor subunits are plausible candidates for a functional role in mediating nicotine effects on addiction.
In the next paragraphs, we will concentrate on the CNS expression patterns of some specific nAChRs genes. It is important to note that most gene expression data have been obtained from rodents or monkeys. Because of species differences in regional expression, care should be taken when extrapolating such results to humans. 18, 34 CHRNA2. A study of CHRNA2 expression in rats and mice detected a2-mRNA expression in the midbrain regions (including VTA and IPN) as well as in several cortical layers. 53 In primate cortex, a2-containing receptors were highly expressed in monkeys and humans, making this subunit expression pattern in the brain species specific. 18, 48, 54 CHRNA3. The a3-subunit is highly expressed in the PNS 55 mainly in the a3b4* receptor. In addition, a3-containing nAChRs are found in several regions of rodent brain, including the VTA, pineal gland, medial habenula, IPN, brainstem nuclei, hippocampus and cerebellum. [56] [57] [58] CHRNA5. In humans, mRNA encoding the a5-nicotinic subunit has been detected in several structures of the nervous system (including cortex) but appears to be mainly expressed in the cerebellum and thalamus (where it assembles with a4b2* and a3b2* receptor subtypes) and the autonomic ganglia. 59 In particular, a4b2a5-containing receptors are expressed on dopaminergic neurons in rat and mouse striatum and are involved in DA release due to nicotine stimulation. 60, 61 In addition, a5-containing receptors are expressed on GABAergic neurons in the striatum and VTA.
CHRNA6. In mouse and rat CNS, a6-and b3-subunits colocalize in dopaminergic neurons and retina 62, 63 as a6b2b3* or a4a6b2b3 nAChRs. [64] [65] [66] a6 nAChRs are expressed in higher concentration on nerve terminals than on cell bodies or dendrites, suggesting that a6 or another subunit (such as b3) plays a targeting role. 32 The a6-subunit is found at high levels in catecholaminergic nuclei, including the locus coeruleus and superior colliculus and VTA. In rat and mouse striatum, a6b2* and a4(non-a6)b2* are the major nAChR subtype populations, differently expressed by dopaminergic and non-dopaminergic neurons, and involved in mediating the release of DA. 32, 60, 64, 67 CHRNB3. Several reports show that b3-containing nAChRs have a physiologically significant role in dopaminergic neurotransmission and many nAChRs expressed on mice substantia nigra-VTA dopaminergic neurons are b3-dependent.
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In addition to midbrain and striatum, b3-containing receptors are also found in the mouse superior colliculus, lateral geniculate nucleus and retina.
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CHRNB4. The nicotinic b4-subunit is widely expressed in the mouse PNS, but in the CNS it has a restricted expression pattern. The b4-containing nAChRs are expressed at relatively low densities in the rat and mouse substantia nigra and VTA. 43, 70 Indeed, besides the olfactory bulb and pineal gland, the b4-subunit is expressed in the CNS at high levels only in the medial habenula and IPN 43, 71, 72 CHRNA9 and CHRNA10. The expression of a9-and a10-subunits in inner hair cells and their role in cochlear innervation in rats and mice are well documented. 73 These receptors are also expressed in dorsal root ganglions neurons and pituitary, 74 but according to current knowledge, they are not found in other regions of the brain. 18 
Genetics of ND-related phenotypes
In the following section, we provide an overview of recent findings on the association of nAChR gene variants with ND-related phenotypes (Table 2) , highlighting issues to consider in the context of genetic research. Three research methods have been used: linkage analysis, candidate-gene association studies and genome-wide association studies (GWAS).
According to a recent review by Li, 3 more than 20 genome-wide linkage analysis studies for various NDrelated behaviors have been conducted in different populations. Thirteen regions, located on chromosomes 3-7, 9-11, 17, 20 and 22 (two different regions on chromosomes 5 and chromosome 9) were found to show suggestive or significant results in at least two independent samples, with regions on chromosomes 9, 10, 11 and 17 receiving the strongest support. 3 Three of the nAChRs are located in these suggestive or significant regions: CHRNA 2(8p21-22), CHRNA4 (20q13.2-q13.3) and CHRNA10 (11p15).
The second approach, candidate-gene studies, has been used for several years to study the nAChR gene association with ND phenotypes, primarily using single-nucleotide polymorphism (SNPs). The studies have been performed in family-based (for example: Feng et al.
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) or case-control designs (for example: Saccone et al. 76 ). In general, many different genes of various biological functions have been associated with ND-related phenotypes, but prominent association was found with several neuronal nAChRs genes, as discussed below (for recent review, see Portugal and Gould 77 ) . The third and newest technique is GWAS. Several GWAS finding have been reported in the last 2 years, using sets of 300-500 000 SNPs and including large numbers of participants. Impressive associations were reported for the CHRNB3/CHRNA6 gene cluster 78 and for variants in the CHRNA3/CHRNA5 cluster. 79, 80 However, other GWASs do not support strong association of nAChRs with ND phenotypes. 15 ND is a complex phenomenon encompassing several aspects. Thus, it is not surprising that many different ND-related phenotypes have been used by researchers in genetic studies. Four major phenotype 
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HSI score (0-6 point scale) Li et al.
87
Smoking quantity-cigarettes per day (CPD) Extremes phenotype: controls always smoked < 5 CPD; cases smoked > than 25 CPD Berretini et al.
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Extremes phenotype: controls always smoked < 5 CPD; cases smoked > than 30 CPD Stevens et al.
90
Extreme phenotype: cases > 5 CPD; control smoked 1-100 cigarette in lifetime, but not regularly Sherva et al.
89
Habitual smoking: affected smoked > 20 CPD for 6 months or more; unaffected smoked < 10 CPD.
Bierut et al.
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Smoking quantity levels: 0 (1-10 CPD), 1 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) 
83
Smoking cessation treatment outcome Self-report of smoking abstinence and low carbon monoxide reading Hutchinson et al.
112
Number of unsuccessful quit attempts Hoft et al.
109
Smoking cessation probability Breitiling et al.
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Abstinence rates at end of treatment and after a 6 month follow-up period Conti et al.
116
Time to relapse Conti et al.
Withdrawal symptoms at target quit date Conti et al.
Successful versus unsuccessful quitters (for at least 6 weeks after completion of trail) Uhl et al.
15
Time to cessation (in ever heavy smokers) Breitiling et al.
91
Other phenotypes Revised tolerance questionnaire (RTQ) Feng et al. Smoking initiation is considered as a separate phenotype from ND. Genetic and environmental factors that influence SI may be different from those that influence ND, although they may also be shared. 12, 81 Age of SI (and its influence on later life smoking behavior) is another phenotype that has been studied from the genetic perspective (Table 2) . 82, 83 Development of ND requires exposure to nicotine. Therefore, the most appropriate controls for studying factors that influence severity of ND in smokers are individuals who initiated smoking and had sufficient exposure to develop ND but did not. This approach was implemented by Sacconne et al. 76 and Bierut et al.
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Implementation of each phenotype category requires availability of specific data, which is dependent on a priori study design. As a result, there is great variability in the ND phenotypes that are used and this is an important factor limiting the replicability of findings. A further consideration is that testing a series of different phenotypes in the same study raises concern regarding spurious findings that are a consequence of multiple testing. The fact that the different phenotypes are mostly highly correlated may somewhat mitigate this concern. Formal evaluation of the degree of correlation among different ND phenotypes is greatly needed and would enhance efforts to compare studies that use different phenotypes.
The instruments used to assess severity of ND differ from study-to-study, causing inconsistency in defining ND phenotypes. One of the most accepted measurement tools is the Fagerstrom test for nicotine dependence (FTND), which is based on the Fagerstrom tolerance questionnaire (FTQ) 84 with several improvements. The FTND questionnaire focuses on assessing the intensity of nicotine physiological dependence (0-10 score, higher score means higher ND). 85, 86 Heaviness of smoking index (HSI) is composed of two FTND items, smoking quantity (SQ) or maximum cigarettes smoked in a 24 h period. 3 Several distinct FTND/FTQ-based ND phenotypes (with different FTND cut-off scores for case and control) have been described and used for case-control association analysis (Table 2) .
Power considerations are important in evaluating findings.
14 The sample sizes of the studies mentioned below are very heterogeneous, from B200 to more than 20 000 participants. A further consideration is that spurious findings may occur due to multiple testing that inflates false-positive rates.
14 Also, the ethnic origin of the samples should be taken into consideration when comparing the results of studies.
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CHRNA5-CHRNA3-CHRNB4 cluster Recently, a plethora of evidence has accumulated suggesting the involvement of this gene cluster in ND in particular and in substance abuse in general. This 15q25.1 locus contains three genes encoding nAChRs subunits, which lie very close to and in strong linkage disequilibrium (LD) with each other, so that most reports treat them as a cluster. To date, evidence for genetic association of these nAChRencoding loci with ND-related phenotypes is more robust and convincing than evidence for any other nAChR gene association with ND. Emphasis should be given to the fact that in the case of CHRNA5-CHRNA3-CHRNB4, GWAS findings, which are considered superior to candidate-gene designs because of their 'hypothesis-free' approach, validate and converge with candidate-gene studies of nAChR genes that are based on the biologically plausible role of these genes in mediating nicotine influence in the brain. This unexpected outcome of the GWAS strongly supports the rationale of the candidate-gene approach in ND.
CHRNA5-CHRNA3-CHRNB4 cluster and ND. In the candidate-gene study of Saccone et al., 76 seven SNPs located within the CHRNA5-CHRNA3-CHRNB4 cluster were associated with ND. This large 348 candidate-gene study, accompanied by a GWAS performed in parallel, 78 included a European ancestry (EA) sample of 1050 cases and 879 controls from the United States and Australia. In both studies, cases were defined as individuals with scores X4 on the FTND, whereas controls were people who had been exposed to smoking (must have smoked at least 100 cigarettes in their lifetimes) but had an FTND score of 0 during the heaviest period of smoking. As noted above, this control selection strategy allows genetic effects specific to ND to be examined more effectively.
Biologically, the most plausible evidence for a risk variant was for the non-synonymous SNP, rs16969968, in the CHRNA5 gene (P = 0.00064). 76 Individuals with two copies of the minor allele 'A' (causing substitution of the 398 amino acid asparagine with aspartic acid) were nearly twice as likely to have ND, in a recessive model of inheritance. There was even stronger association of the CHRNA3 3 0 UTR SNP, rs578776 (P = 0.0003). Five other SNPs in the cluster showed impressive association with ND in this sample: rs1051730, rs684513, rs637137, rs3743078 and rs3813567. 76 A recent paper from this group 88 validated and refined the finding in a sample different from the shared Saccone et al. 76 candidate gene/Bierut et al.
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GWAS sample and consisting of 1236 individuals from 219 pedigrees of European descent . In a sample originally collected for the study of alcoholism, the affected persons were defined as smoking 20 cigarettes a day for at least 6 months and the unaffected persons as smoking 10 cigarettes or fewer per day. Two distinct, independent genetic associations with habitual smoking were found, with low correlation between them. The first is marked by rs16969968 (P = 0.007) and the second by rs578776 (P = 0.009).
The absolute value of D 0 is high, but the correlation between 16969968 and rs578776 is low (r 2 < 0.15), rendering them statistically independent. As expected, other SNPs that were highly correlated with rs16969968 (rs1051730, rs2036527, rs17486278 and rs17487223) were also associated with habitual smoking (P = 0.02-0.086). 88 To evaluate the effect of the CHRNA5 non-synonymous SNP, rs16969968 (aspartic acid to asparagine in 398 position), on receptor function, changes in intracellular calcium after nicotine agonist exposure were measured in HEK293T cells expressing either a4b2a5D398 or a4b2a5N398 nAChRs. The receptor with the aspartic acid variants (D) showed a greater maximal response to nicotine than N398 receptors. However, no difference was shown in the isoform expression. 88 Berrettini et al. 79 also obtained evidence for the relevance of the CHRNA5-CHRNA3-CHRNB4 gene cluster to ND in a GWAS (by Affymetrix 500K SNP chip) in two European populations combined into a sample of B7600 individuals, but used a different phenotype, consumption of cigarettes per day (CPD). For dichotomous cases-control analysis, cases were defined as individuals smoking more than 25 cigarettes per day, whereas controls reported CPD less than 5. The CHRNA3 SNP rs6495308 was significantly associated with CPD consumption (pooled Pvalue of 0.000069), and the CHRNA3 SNP rs951266 in a sub-sample. However, no SNP reached the required GWAS level of significance, 10 -7 . Another CHRNA3 intronic SNP, rs1317286, was strongly associated with CPD in a third sample of B8000 persons (P = 0.0000026) (using a panel of B6000 SNPs in B2000 genes). 79 Unfortunately, there were no genotyped SNPs common to those described in the papers of Saccone et al., 76 Bierut et al. 78 and Berretini et al. An important replication of these finding comes from a GWAS of SQ in B11,000 Icelandic smokers. 80 This GWAS clustered the SQ phenotype, into four levels: 0 (1-10 CPD), 1 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , 2 (21-30) and 3 (31 and more). Allele T of the rs1051730 SNP in CHRNA3 was most strongly associated with SQ (P = 5 Â 10 À16 , surviving a significance threshold of 2 Â 10 À7 ). This is one of the variants reported by Saccone et al.
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rs1051730 was then tested in a subset of 2394 Icelandic smokers (defined as FTNDX4, or fulfillment of at least three out of seven DSM-IV criteria) vs 3506 low-quantity smokers, as a measure of ND resembling the Saccone et al. 76 phenotype and was significant with P = 7 Â 10 À15 and an odds ratio (OR) of 1.4. As smoking is also a risk factor to lung cancer (LC) and peripheral vascular disease, association of the rs1051730 SNP was analyzed and found significant for both diseases (P = 1.5 Â 10 À8 and 1.4 Â 10 À7 , respectively, in combined samples).
A relatively small case-control study (435 participants) of Sherva et al. 89 focused on the rs16969968 SNP. Besides replication of association of this SNP with smoking status by itself (cases smoked more than five cigarettes a day for more than 5 years, whereas controls smoked between 1 and 100 cigarettes in their lifetime) (P = 0.01), the researchers explored association of this variant with early smoking experience. On the basis of the retrospective report of feelings on smoking the first cigarette, the rs1696968 SNP was significantly associated with experiencing pleasurable response (buzz or rush) among Caucasians when first smoking (P = 0.01). This feeling was associated with risk of current smoking status (P < 0.0001). 89 In agreement with Bierut et al. study, 88 two different groups of SNPs were associated with ND in a case-control sample of 1452 heavy smokers (CPD > 30) and 1395 light smokers (CPD < 5) of EA. 90 Eight SNPs which are in high LD (including rs16969968 and rs1051730) were associated with increased smoking risk (See Table 3 ), while 11 SNPs (including rs578776) were protective and associated with decreased risk of heavy smoking (See Table 3 ). All associations withstand Bonferonni correction for multiple testing. 90 As reported previously, 88 the correlation between the two separate SNP groups is low. 90 On the other hand, no association of this gene cluster with smoking cessation was found in a large, well-powered retrospective cohort study from Germany. 91 Seven SNPs which are related to other ND phenotypes were genotyped (rs684513, rs637137, rs16969968, rs578776, rs1051730, rs3743078, rs3813567) in a sample of 1446 heavy smoking individuals ( > 20 CPD). No significant association with smoking cessation probability was found, although the study had enough power to detect even small effects. These results suggest that CHRNA5-CHRNA3-CHRNB4 variants contribute to the development of ND, but not to the likelihood of cessation when the ND is already well established. 91 An important reservation is that all the GWAS and case-control studies reviewed above (except the relatively small sample of Sherva et al.
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) were conducted on European origin samples. Individual SNP associations may be different, or even not exist at all, among diverse ethnic groups. For example, the frequency of the rs16969968 SNP is dramatically different in EA (37%) and African populations (0%). 88 Further replication of these findings in other ethnic groups is warranted. 
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CHRNA5-CHRNA3-CHRNB4 involvement in agedependent nicotine addiction. In accordance with the observation that onset of smoking during adolescence is associated with more severe ND in adult smokers, 82, 92, 93 Weiss et al. 82 studied a sample of 2827 long-term smokers, using a dichotomized definition of ND severity based on FTND scores: low (FTND = 0-4) and high (FTND 6-10). Six SNPs were significantly associated with ND with P-values ranging from 0.0032-0.0005 (including rs1699968, rs1051730 and rs578776) only in the early onset of smoking group (age 16 years or younger), but not in the late onset group (age 17 years or older).
In a five tagging SNP (rs680244, rs569207, rs16969968, rs578776 and rs1051730) haplotype analysis of the CHRNA5-CHRNA3-CHRNB4 cluster, one haplotype (CCAGA) was detected to be a risk factor, while another (CTGAG) was a protective factor for smoking heaviness in adults. 82 These predispositions were strongest if smoking began during adolescence. These finding are in correlation to those reported by Stevens et al., 90 who found two groups of SNPs in this cluster; one increased risk for heavy smoking, while the other was protective.
CHRNA5-CHRNA3-CHRNB4 and other substance abuse. Comorbidity of nicotine and alcohol use is well documented but a common biological mechanism or genetic background has not been shown. 9, 83 Association of the CHRNA5-CHRNA3-CHRNB4 locus with alcohol dependence (defined by DSM-IV) was shown for 16 polymorphisms (out of 42 genotyped) in two samples, spanning the CHRNA5-CHRNA3 region and including a SNP (rs588765) that affects mRNA levels. 94 These variants show low LD with most other ND associated SNPs reported earlier.
Further evidence for a possible shared genetics background is supplied by Joslyn et al. 95 who reported association of several SNPs in the chromosomal region of CHRNA5-CHRNA3-CHRNB4 locus (particularly rs1051730 and rs8034191) with alcohol level of response, which is considered an intermediate phenotype for alcohol addiction. 95 Age at initiation of both tobacco use and alcohol drinking was significantly associated with three other SNPs within the CHRNA5ÀCHRNA3ÀCHRNB4 locus (rs8023462, rs1948, rs514743) in a US sample of 1075 individuals of diverse ethnicity. rs8023462 and rs1948 significantly predicted early age of initiation for tobacco with a hazard ratio of 1.35 for the TT genotype of rs8023462 and a hazard ratio of 1.29 for the CC genotype of rs1948. 83 These findings were replicated in a separate population-representative sample, and together they suggest that variants in this gene cluster may influence and promote the early use of tobacco and alcohol. 83 Furthermore, the association of rs16969968 and rs1051730 with both ND (phenotype was defined as FTND score) and symptoms of alcohol use and dependence (according to DSM-IV criteria, in another sample) was reported by Chen et al. 96 The ND association was shown in two samples of 815 and 1128 EA individuals, and the association remained significant after correction for multiple testing. However, no association of any of the seven SNPs genotyped in the region was found with cannabis abuse or dependence, in a separate sample. 96 A recent study has shown association of the CHRNA5 non-synonymous SNP, rs16969968, with cocaine dependence. 97 Association of this SNP with ND-related phenotypes was extensively described above. Interestingly, while the minor allele (A, causing aspartic acid to asparagine substitution) is a risk factor for ND, it plays a protective role in cocaine dependence. 97 The association of the same gene cluster with several drugs of abuse (nicotine, alcohol and cocaine dependence) may imply a common, general neurobiological mechanism of brain nAChR involvement in drug addiction, possibly because of cholinergic system modulation of DA release and DAmediated reward pathways.
CHRNA5-CHRNA3-CHRNB4 and LC.
Smoking is the most important risk factor for LC. 1, 98 In the nineteenth century, LC was considered a rare disease. 99 Since the turn of the twentieth century, when cigarette smoking became widespread in the developed world, LC rate increased dramatically. 98, 99 However, the clear epidemiological link between LC and smoking was proved conclusively only in the 1950s. 98 Two recent GWASs reported association of the CHRNA5-CHRAN3-CHRNB4 locus with LC but not with ND. In a large GWAS, B317 000 SNPs (Illumina HumanHap300 Beadchip) were analyzed in B2000 LC patients and 2625 controls of central European origin and in five additional samples. 100 The nonsynonymous SNP, rs16969968, and rs8034191 (most significant marker for LC, located in the nearby gene PSMA4), which are in strong LD and highly correlated (D 0 = 1; r 2 = 0.92), were found to be robustly associated with LC (rs16968869: allelic OR = 1.3, P = 1 Â 10 À20 overall; rs8034191: allelic OR = 1.3, P = 5 Â 10 À20 overall). The statistical risk for LC was observed irrespective of smoking status and was increased by these variants in current, former and never smokers groups. However, no association was detected with head and neck cancers (another smoking-related cancer). To rule out the association of the 15q25 locus with LC through its involvement in ND, the association of rs16969968 with ND was analyzed in a subsample (for which smoking behavior data were available), but no association with any of the individual FTQ indices or the HSI measure was found. Other LC associated SNPs in the region are rs1051730, rs951266 and rs1317286, but they were not analyzed for ND. 100 The authors of this GWAS state that the association with LC is unlikely to be mediated by the association with ND, as the increased risk was also seen among nonsmokers and was not seen in other smoking-related cancers. 100 Genetic
Further support for the importance of the CHRNA5-CHRNA3-CHRNB4 locus in LC comes from a GWAS of B1150 current and former smokers and B1150 controls that analyzed 315 450 tagging SNPs (Illumina HumanHap300 Beadchip) and showed that the CHRNA3 SNP, rs1051730, and the neighboring PSM4 SNP, rs8034191, are associated with LC, with a combined, adjusted OR of 1.32 (P = 7 Â 10 À18 ) for rs1051730 and an OR of (P = 3.5 Â 10 À18 ) for rs8034191. 101 This association was confirmed in two replication sets. When the two SNPs were analyzed for association with two measures of ND (CPD and pack-years of exposure), there was only weak evidence for an influence on smoking behavior, among former but not current smokers.
These findings conflict with those of Thorgeirsson et al., 80 who showed that a sequence variant associated with ND conferred risk for LC and peripheral vascular disease through an effect on smoking behavior. Robust evidence for association with ND comes from the reports of Saccone et al. 76 , Bierut et al. 78 and Berretini et al.
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; these reports do not address association with LC. Nevertheless, in two large GWASs 100,101 direct and significant association with LC was shown, with weak evidence in only one of them for association with ND.
Since the appearance of these three pivotal GWASs, intensive research efforts have been invested to elucidate the relationship of these loci to LC, but there are no clear conclusions. A systematic and comprehensive description of all the observations is beyond the scope of this review, which focuses on the role of nAChRs in ND. It is noted that the association of the rs8034191 and rs1051730 SNPs with familial LC was described by Liu et al. 102 in the context of GWAS performed on a 194 familial LC patients and 219 control individuals sample (adjusted for age, sex and pack-years of cigarette exposure). However, data regarding ND in terms of FTND scores were unavailable. 102 In a very recent follow-up publication to the GWAS of Amos et al. 101 Spitz et al. 103 combined the discovery and one of the replication samples and observed that the highly correlated rs1051370 and rs8034191 are significant risk factors for both LC and ND, contrary to the initial conclusions of Amos et al. 103 (Supplementary Table 1 ). Two ND-related phenotypes were found to be significantly associated: CPD and FTND, but not other phenotypes such as age of SI. 103 In contrast, when rs1051730 was tested among lifetime never smokers, no association with LC was found, supporting the etiological assumption that LC etiology is mediated by ND and these SNPs do not contribute per se to carcinogenesis. These nAChR receptors are expressed in human and rodent bronchial epithelial cells, 104 and in non-small-cell lung cancers. 105 We do not know at this time whether polymorphisms in this cluster can directly increase the sensitivity of the target tissues to tobacco smoke and/or nicotine toxicity. 106 Besides the option that variants in the CHRNA5-CHRNA3-CHRNB4 loci increase LC risk solely due to involvement in increased smoking, it is also possible that genetic variants in nAChRs directly influence mechanisms of lung carcinogenesis, without mediation by smoking phenotypes. A third option is that these same loci are involved independently in the pathophysiology of both states. 107 If so, combination of high nicotine consumption and higher LC susceptibility would be synergistic. These controversial findings underscore the challenge of defining and measuring behavioral phenotypes (although some ND-related phenotypes seem at first glance quite simple to define; for example, CPD). This may be a plausible explanation of why associations with ND-related phenotypes are more difficult to demonstrate than the associations with LC.
The relationship of CHRNA5-CHRNA3-CHRNB4 loci with ND versus LC should be studied in the future, taking into account the histological characteristics of LC, interindividual variability of nicotine metabolism and parallel exposure to other carcinogens. Finally, as at least two independent variants within this cluster are associated with ND risk, it is possible that the LC risk variants within the gene cluster are independent and uncorrelated with at least one of the ND SNPs, notably the CHRNA3 3 0 UTR rs578776.
CHRNB3-CHRNA6 cluster
A large body of evidence supports a contribution of the CHRNA6-CHRNB3 gene cluster to ND (Table 3) . The strongest findings stem from the GWAS of Bierut et al. 78 and the 348 candidate-gene study of Saccone et al., 76 which are described above (Section 'CHRNA6-CHRNB3-CHRNB4 cluster and ND'). In the candidate-gene study, two SNPs in CHRNB3, rs6474413 and rs10958726, which are in very high LD and located in the putative 5 0 promoter region, accounted for the strongest signals in the analysis. Two synonymous coding SNPs in exon 5 of CHRNB3, rs4952 and rs4953, and rs2304297 located in 3 0 UTR of CHRNA6 were also among the top signals. 76 Converging evidence for association of CHRNB3 with ND came from the results of the GWAS, 78 in which the gene appeared in the 'top-group'. rs13277254 had a P-value of 6.54 Â 10 À5 , and was the 21st strongest signal in the GWAS out of 31 960 SNPs genotyped with a custom array, with an OR of 1.19 among males and an OR of 1.55 among females. However, this association does not withstand correction for multiple testing. 78 The SNP (not genotyped in the parallel candidate-gene study) is located 3 kb upstream of the CHRNB3 5 0 promoter. In the study of Stevens et al.,
90 described in detail above, two SNPs were nominally significantly associated with heavy smoking (rs7012713 in CHRNB3 and rs7828365 in CHRNA6), but both did not survive correction for multiple testing. On the other hand, no association with heavy smoking in this sample was detected for any of the six ND-related CHRNB3-CHRNA6 SNPs reported by Saccone et al. 76 and Bierut et al.
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Genetic
A recent study 108 focused on the association of four SNPs in the CHRNB3-CHRNA6 loci with early subjective response to tobacco. Initial subjective response to tobacco is important for reinforcement mechanisms and may be an endophenotype for ND, acting as a mediator between the genotype and dependence, differentiating individuals who develop ND over time from those who do not. 89 The participants were retrospectively asked about early subjective responses when they started smoking, by answering 23 questions such as 'In the period shortly after you used tobacco, did it make you feel (subjective effect)?' to which individuals answered yes or no. The subjective effects were grouped into three factors: negative physical (lazy, drowsy and so on), positive (creative, sociable, energetic and so on) and adverse (depressed, paranoid, confused and so on). Two independent US samples (1056 ethnically diverse adolescents and 1524 families) were studied. 108 The rs4950 and rs13280604 SNPs, located in the CHRNB3 5 0 UTR and intron 1, respectively, were robustly associated with all three subjective response factors to initial tobacco use, in both samples. Significant results were also detected for the other two SNPs genotyped, rs4953 (found to be associated with ND in the Saccone et al. 76 study, as mentioned above), hCV25772398, and haplotypes composed of the four SNPs. However, no association was shown between these SNPs and patterns of use of either tobacco or alcohol. Strong limitations of this study are reliance on retrospective reports of young individuals, multiple testing and the possibility that other substances were tried in the same period of experiencing tobacco and alcohol. 108 Hoft et al. 109 investigated the association of eight SNPs in the CHRNA6-CHRNB3 cluster with smoking behavior in a representative sample of US households, which included 1051 participants, nearly half of them members of sibling pairs. 109 ND was assessed using DSM-IV criteria and individuals who endorsed three or more of the seven dependence symptoms were considered dependent. The second phenotype was the number of unsuccessful quit attempts. In a family-based sample, the CHRNA6 rs2304297 SNP and rs13280604 in CHRNB3 were associated with three or more dependence symptoms among current Caucasian smokers. When unrelated singletons (in the whole sample or within a current frequent smokers sub-population only) were examined for genetic association with ND, nominal association was detected in these two SNPs, as well as in CHRNB3 rs7004381 and rs4950 and CHRNA6 rs892413. 109 Four SNPs in the CHRNB3 gene (rs7004381, rs4950, rs4953 and rs13280604) and one CHRNA6 SNP, rs2304297, were associated with number of quit attempts, regardless of ethnicity. Only the association of rs7004381 with quit attempts survives Bonferonni correction. 109 In the Stevens et al.
90 study, which is described in detail above, two SNPs were nominally significantly associated with heavy smoking (rs7012713 in CHRNB3 and rs7828365 in CHRNA6), but both did not survive correction for multiple testing. Nominal associations of rs9298629 (P = 0.035, genotype) and rs1072003 (P = 0.053, genotype) with severity of ND were reported by Greenbaum et al., 81 in a small sized case-control study of 11 nAChRs gene among female Israeli students aged 20-30 years, divided into high (n = 127) and low ND (n = 115) groups. 110 The nearby CHRNA4 gene is positioned at B98 cM on chromosome 20, although the evidence for linkage to this gene in the analysis was weak. In a genome-wide permutation linkage study of the Framingham Heart Study (FHS) population using 401 autosomal microsatellite markers, significant linkage of the marker region D20S481-D20S480 with SQ was reported (interval 78-86 cM, peak 84 cM, genome wide P = 0.032).
CHRNA4
Two genome-wide linkage analyses found significant or suggestive linkage of the 20q13.2-q13.3 region to smoking behavior. Significant evidence for linkage of marker region DS20119-DS20S178 with maximum number of cigarettes smoked in a 24-h period was found in a Finnish sample of 623 individuals from 155 families; the peak multipoint LOD score was 4.22 at 72.90 cM.
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Several candidate-gene studies have shown evidence for possible association of the CHRNA4 gene with ND phenotypes. Two synonymous SNPs, rs1044396 and rs1044397 in exon 5 of the gene, were significantly associated with a protective effect against ND, in a sample of 621 males from 206 families with multiple nicotine addicted siblings from Anhiu province, China. 75 For both SNPs (which are in almost complete LD), significant associations were found for all three addiction-related phenotypes measured: addicted cases (FTND scores > 8) vs nonaddicted controls (FTNDr2), age adjusted FTND and RTQ (revised tolerance questionnaire) scores (quantitative phenotypes). Association of the rs1044397 SNP with age-adjusted FTND and RTQ scores survived Bonferonni correction. A haplotype composed of all six SNPs genotyped in the CHRNA4 gene (including rs1044396 and rs1044397) with 22.5% frequency in the population was significantly associated with protection against ND. 75 Li et al. 87 analyzed the association of six SNPs in the CHRNA4 gene with SQ, FTND and HSI in 2037 individuals from 602 nuclear families of EA or Africans American (AA) origin. Association of rs2236196 with all three measures was reported in the AA subsample, and remained significant for HSI and FTND after correction for multiple testing. In the EA subsample, SNPs rs1044396 and rs2273504 were associated with SQ and FTND, respectively. Haplotype analysis of rs2273505-rs2273504-rs2236196 showed significant association withstanding multiple testing with all the ND measures in AA females. 87 The same CHRNA4 3 0 UTR SNP, rs2236196, was found to be associated with the subjective physiological effects of smoking and the experience of a rush Genetic variation in multiple brain nAChRs and ND L Greenbaum and B Lerer or high, in a sample of 316 participants of diverse ethnicity tested for subjective responses to smoking in the laboratory. 112 After 8 h of smoking abstinence, each participant smoked three high-nicotine cigarettes, and was then assessed for four-dimensions of behavioral sensitivity to nicotine (endophenotype of ND): (1) physiological, (for example, nausea and heart pounding), (2) rush or high, (3) cognitive and (4) reward. A subjective response of reward was associated with the 5 0 promoter SNP rs6122429. Subsequently, the same research group reported that rs2236196 was associated with smoking cessation outcomes, in the context of a clinical trial of transdermal nicotine patch versus nicotine nasal spray for smoking abstinence (there were no significant difference in rs2236196 genotype between the two treatment groups). Smoking abstinence was assessed by self-report and exhaled carbon monoxide reading. Among the 353 participants in this trial, rs2236196 was associated with smoking abstinence at the end of treatment and 6 months later (P = 0.01). 112 To investigate the biological relevance of these two SNPs, luciferase activity of a construct containing the two different alleles was assayed as a marker for gene expression. 112 The construct containing the T allele of the 3 0 UTR rs2236196 SNP showed greater luciferase activity than the construct containing the C allele. In postmortem brain tissue, a4b2-receptor binding in the NAc was greater among carriers of the TC genotype than carriers of the TT genotype. 112 Regarding the rs6122429 promoter SNP, luciferase activity in the construct containing the G-allele was fivefold greater than the A-allele construct, probably due to a difference in transcription factor binding to this promoter region. This unique study design of several levels of experimental approaches (cell culture, receptor binding in postmortem brain tissue, subjective effects in a human laboratory model and treatment outcome data) provides important information regarding how genetic variation may affect ND phenotypes at the biological level. 112 Association study of the CHRNA4 gene and heavy smoking among schizophrenia patients showed significant association between rs3746372 and large number of cigarettes smoked daily, as well as interaction between this SNP and rs3787116. 113 Schizophrenia patients are frequent (up to 80%, a much higher rate than in the general population) and heavy smokers, and the association between schizophrenia and smoking is of special interest. Tobacco use is thought to alleviate neurocognitive deficits(s) of this disorder and to be an attempt of self-medicate.
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CHRNB2
Greenbaum et al. 81 genotyped 39 SNPs located in 11 nAChRs genes in a sample of Jewish, Israeli women, all undergraduate students aged 20-30 years. The sample consisted of 142 non-initiators of smoking and 242 initiators (SI) of whom 127 were defined as high ND (FTQX6) and 115 were low ND (FTQ < 4) . The rs2072660 SNP in CHRNB2 was nominally associated with SI (P = 0.02 for allele; P = 0.015 for genotype). Multi-SNP haplotypes, including rs2072660, were protective against SI (P = 0.036). None of the findings withstood correction for multiple testing. 81 Association of the rs2072658 SNP, located 42 bp upstream to the CHRNB2 transcription initiation site with initial subjective response to both tobacco and alcohol, was reported by Ehringer et al. 115 in a sample of 1068 ethnically diverse young adults (mean age B18 years). The research assessment tools, methods and limitations are similar to those described for this type of study in relation to CHRNB3-CHRNA6 108 in Section 'CHRNA5-CHRNA3-CHRNB4 cluster'. rs2072658 was associated with two tobacco phenotypes: tobacco negative physical and tobacco positive. Interestingly, the same SNP was also associated to two alcohol phenotypes: alcohol negative physical and alcohol adverse. rs2072660, located in CHRNB2 exon 6, was associated with another tobacco phenotype, sensitive, which relates to feeling 'nauseous' or 'dizzy'. However, no association of either SNP was found with pattern of use. 115 The rs2072661 SNP in the 3 0 UTR region of CHRNB2 was associated with success of pharmacotherapy for ND. Conti et al. 116 performed a study of 58 candidate genes (genotyping 1295 SNPs) in a sample of 222 individuals receiving bupropion and 195 receiving placebo (all of EA). Independent of treatment, rs2072661 was associated with abstinence rate at the end of treatment (adjusted P = 0.01), and after a 6-month follow-up period (adjusted P = 0.0002, significant with adjustment for the number of genes tested). The highly correlated 3 0 UTR rs2072660 SNP had a similar impact on these phenotypes. Furthermore, rs2072661 had a role in the time to relapse and withdrawal symptoms at target quit date. 116 However, several independent studies did not demonstrate significant association of CHRNB2 with smoking-related behaviors or ND phenotypes (for both individual SNPs and haplotypes). In the Feng et al.
75 study (research details described in Section 'CHRNA4') rs2072658 and rs2072660 discussed above, as well as other SNPs including rs2072661, did not show significant association with ND. Negative results for the same SNPs were reported in two independent US samples-the study by Silverman et al., 117 in which an association with SI or ND (similar phenotypes to Greenbaum et al.
81
) was studied, and that by Li et al., 87 described in Section 'CHRNA4'. No significant associations of individual markers or haplotypes with smoking risk and behavior were detected by Leuders et al., 118 and by Voineskos et al., 113 in a sample of schizophrenic smokers. In the study of Stevens et al., 90 no associations with heavy smoking were found for 10 SNPs analyzed within the CHRNA4 and CHRNB2 genes.
Recently, highly significant gene-gene interactions for the gene pairs CHRNA4-CHRNB2, CHRNB2-NTRK2, CHRNA4-BDNF and CHRNA4-NTRK2 were reported with regard to ND in a case-control sample. 119 The SNPs included in the CHRNB2-CHRNA4 gene pair interaction model were rs2072660, rs2072661 (CHRNB2) rs2273504, rs2229959 and rs2236196 (CHRNA4). 119 The importance of these findings lies in the notion that although a contribution of CHRNB2 to ND may not be observed when this gene is analyzed separately, it may still be involved in ND, due to dependency of a CHRNB2 effect on specific variants in other genes (CHRNA4 or NTRK2). Conventional single-gene association analysis may not be useful in the case of CHRNB2 and its role in ND genetic would need to be analyzed jointly with other genes. 119 Other nAChR loci Compared with the data regarding the four loci presented above, less evidence supports involvement of four other nAChR loci (CHRNA2, CHRNA7, CHRNA9 and CHRNA10) in genetic susceptibility to ND.
CHRNA2.
A few genome-wide linkage analysis studies showed some degree of significant or suggestive evidence for the 8q21 region with peak scores close to CHRNA2. In the SMOFAM sample of 607 individuals from 158 families, in which 738 autosomal, microsatellite markers were examined, 120 the D8S258 marker was linked to tobacco dependence, using a phenotype based on DSM-IV (fulfillment of three or more out of seven ND criteria during lifetime) with maximal LOD score of 2.7. This linkage supports data from the Collaborative Study on the Genetic of Alcoholism (COGA) that used two phenotypes (ever smoked and average number of packs per year) with both showing modest linkage to 8p22-23. 121 CHRNA2 has also been implicated in a smoking intensity phenotype among schizophrenic pedigrees of European American and AA origin in a linkage study using the permutation method. The highest peak LOD score of 2.34 in the CHRNA2 containing 8p21-22 region (P-value 0.001) was shown for the marker D8S258 in the EA sample (P-value of 0.003 in the combined sample, with LOD score of 1.91). 122 The CHRNA2 3 0 UTR SNP, rs2280376, was nominally associated with antisocial drug dependence during adolescence, in a sample of 231 young Caucasian American males in treatment for drug dependence and delinquency versus matched community controls. 123 Analyzing 1500 SNPs distributed across 50 candidate genes, rs2280376 emerged with a P-value of 0.002 after permutation. Another intronic CHRNA2 SNP, rs2565065, was nominally associated with smoking cessation, in a clinical trial of bupropion versus placebo for smoking cessation in an EA sample, using Bayesian analysis of a panel of 59 SNPs in 11 candidate genes.
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CHRNA7. Although a large body of neurobiological evidence supports an important role for the CHRNA7 gene in ND, its genetic contribution to ND has not been extensively studied. In the Jewish, Israeli female sample of Greenbaum et al., 81 the CHRNA7 intron 4 SNP, rs1909884, showed nominal genotypic association with severity of ND (P = 0.016) (low versus high ND). A logistic regression model predicting high ND and taking into account the effect of background variables showed a significant contribution of two CHRNA7 SNPs, rs883473 and rs1909884, the CHRNA5 SNP rs680244, and the interaction between the CHRNA7 SNP rs2337980 and neuroticism. The model predicted 40% of the variance. No association of this gene with SI was observed. 81 In a report from a Swiss sample, no association of two dinucleotide polymorphisms, D15S1360 and D76630, with smoking status was found.
125
CHRNA7, which is a notable candidate gene for schizophrenia, 126 has been studied in the context of schizophrenia-related smoking (See Section 'CHRNA4'). Association of the 113-bp allele of the D15S1360 marker in CHRNA7 (intron 2) with smoking risk was reported in a sample of 177 schizophrenia patients from Canada. 127 However, no interaction between smoking status and the promoter À86C/T SNP genotype was found by Zammit et al. 128 among UK schizophrenia patients.
CHRNA9 and 10. Suggestive linkage for ND at the 11p15 locus containing CHRNA10 was reported in two independent genome-wide linkage studies. 129, 130 Studying 142 individuals from 12 families (European American) of the Family Study of Panic disorder (FSPD) sample, Gelernter et al. 129 genotyped 416 microsatellite markers and detected linkage of D11S4046 with habitual smoking (P = 0.0003). Affected persons were defined as those who had smoked more than one pack per day for at least a year or at least half pack per day for at least 10 years. In the Finnish twin families sample (FTF), encompassing 505 individuals from 153 families, the linkage findings of Gelernter et al. 129 were supported for ND (FTND X4 scores). D11S4181 had a modest maximal LOD score of 2.25. 130 However, the linkage signal was in the telomeric region, raising questions concerning the reliability of the finding. 130 The study of Greenbaum et al. 81 is, to the best of our knowledge, the only candidate-gene study that analyzed the association of CHRNA9 and CHRNA10 with ND. CHRNA9 was nominally associated with ND severity (intron 3 SNP rs4861065, P = 0.038, genotype) but no positive results were shown for CHRNA10. As mentioned in the Introduction section, these two genes are expressed in the inner ear and not in the brain, making them less plausible for genetic studies.
Genetic manipulation of nAChR genes in mouse models
Genetically modified animals are highly valuable for identifying the physiological and behavioral role of individual neuronal nAChRs subtypes, particularly in the absence of pharmacological agents with specificity for many of the nAChR subtypes. 131 Knock in (KI) and knock out (KO) mutations in nAChR genes provide a useful research tool to evaluate the particular contribution of specific receptor subunits to ND susceptibility, including modulation of dopaminergic transmission by the cholinergic system. 131, 132 Recently, several review papers have addressed physiological and behavioral phenotypes relevant to ND of nAChR gene manipulation in mice. 77, 131, 133 In this short section and the companion table (Table 4 ), we will briefly highlight some of the findings most relevant to the current discussion but not describe them in detail.
CHRNB2
The involvement of the CHRNB2 subunit in the reinforcing effect of nicotine was shown in two elegant studies based on the notion that the reinforcing properties of nicotine are mediated by increasing DA release and transmission in the mesolimbic DA system. The elimination of the chrnb2 gene in KO mice causes a significant decrease in DA release in the ventral striatum after nicotine stimulation as compared with wild-type (WT) animals. 134 Consistently, intravenous self-administration of nicotine is attenuated in these mutant mice. This attenuation is specific to nicotine and there is no effect on the reinforcing of cocaine in the mutant mice. 134 Subsequent work by Maskos et al. 135 confirmed the importance of CHRNB2 for nicotine reinforcement. The researchers used a lentivirus vector to re-express the chrnb2 gene in the VTA of b2-KO mice (the virus was stereotactically injected to this brain region). Reexpression of the chrnb2 subunits caused recovery of nicotine-elicited DA release (recorded using in vivo intracerebral microdialysis in awake, freely moving mice) and nicotine self-administration, as well as restoration of cognitive function, measured by slow exploratory behavior in an open field. 135 Interestingly, b2*-receptors in the VTA and the substantia nigra are involved in different DA-dependent locomotion types (only exploratory behavior for VTA b2*, compared with a variety of locomotion phenotypes for nigral b2*), as observed when b2-gene is rescued in chrnb2 KO mice. 136 On the electrophysiological level, spontaneous firing patterns of VTA dopaminergic neurons are different among b2À/ À mice compared with WT, and re-expression of this subunit restores the original firing patterns. 137 The importance of the b2-subunit in stimulation of DA by nicotine and its relevance to ND is demonstrated by abolition of nicotine-mediated DA responses in b2-KO mice (such as DA-dependent locomotor activation, after repeated nicotine treatment). 138 This suggests that the b2-subunit plays a fundamental role in the sustained activation of the DA system during chronic administration of nicotine. 138 Other behavioral studies in chrnb2 KO mice provide further evidence for the importance of this subunit in nicotine-behavior phenotypes. The b2-subunit plays a major role in nicotine discriminative stimulus and taste aversion effects and these properties may affect psychological aspects of ND. 139 Sensitivity to nicotine's stimulus properties is substantially impaired in b2-KO mice (compared with WT), in two experimental models: drug discrimination and conditioned taste aversion. The effect is specific to nicotine, as no difference between WT and KO is detected with regard to morphine-involved discrimination tests. 139 Mice lacking the b2-subunit do not exhibit nicotine CPP (conditioned place preference), a measure of nicotine reward. 140 The effect of nicotine on acoustic startle response sensitivity was assessed in WT compared with b2-KO mice and a significant reduction in startle amplitude after nicotine administration was detected in the KO mice.
141
CHRNB4
The appearance of withdrawal symptoms after cessation of smoking is an important clinical effect of nicotine. In the study of Salas et al., 72 chrnb4 KO mice had decreased signs of nicotine withdrawal compared with WT. The mice were exposed to nicotine for 13 days (through minipump delivery), and then withdrawal symptoms were induced by intraperitoneal injection of the nicotinic receptor antagonist mecamylamine. Somatic withdrawal symptoms (chewing, scratching, shaking and so on) were scored, and found to be substantially decreased in the KO mice. Hyperalgesia, a non-somatic nicotine withdrawal sign, was induced in WT, but not b4À/À mice. 72 By contrast, no differences in withdrawal symptoms were seen in chrnb2 KO mice compared with WT. Lack of physical nicotine withdrawal symptoms in chrnb2 KO mice was further shown by Besson et al. 142 and Jackson et al., 143 providing robust evidence for this finding. These results suggest that nAChRs subtypes involved in positive-reinforcing mechanisms of nicotine (such as b2-subunits) might be different from those subtypes that contribute to its negative-reinforcing effects (such as b4-subunits).
72
b4-containing receptors are found in the autonomic nervous system, a fact that may explain their involvement in autonomic-mediated somatic signs of nicotine withdrawal.
131
CHRNA6 and CHRNB3
The role of a6-and b3-subunits in the nicotinic modulation of DA neurons and their effects on ND are not completely understood. Both subunits colocalize in striatal dopaminergic neurons. 64 As mentioned before, the b3-subunit has an accessory role and cannot form an acetylcholine binding site. It was noticed that b3-subunit deletion greatly reduces a6* nAChR expression in the DA cell body (VTA) and terminal region (striatum), 32 while mRNA levels for a6 or other subunits were not changed in these areas in b3-KO mice. 68 These findings strikingly support the role of the b3-subunit in a6b3* receptor formation and targeting to DA nerve terminals. 32 Genetic variation in multiple brain nAChRs and ND L Greenbaum and B Lerer 
Genetic variation in multiple brain nAChRs and ND L Greenbaum and B Lerer
Nicotine-related behavior has not been assayed in chrnb3 KO mice but analysis in these mutant mice showed that a sub-population of nAChRs, which both contains the b3-subunit and is sensitive to inhibition by the snail toxin a-conotoxin MII (a-CtxMII), regulates striatal DA neurotransmission following nicotine stimulation. 68 a-CtxMII is a toxin which inhibits nicotine-induced DA release in rat striatal synaptosomes. 144 Deletion of the b3-subunit altered locomotor activity and prepulse inhibition of acoustic startle response, both partially regulated by DA transmission, supporting a role for b3-containing nAChRs in modulating these behaviors. 68 Champtiaux et al. 62 did not find morphological alternation in DA pathways in chrna6 KO mice. Using autoradiography, they found a complete disappearance of a-CtxMII binding in a6À/À mice, claiming that the a6-subunit is an essential component of the native-binding site of this toxin. 62 A recent study has shown the central role of both VTA a6 and VTA a4-subunit in acute nicotine reinforcement.
145 chrna6 KO and chrna4 KO nicotine-naive mice did not display self-administration of nicotine intravenously (at pharmacological doses), whereas WT mice did. When the chrna6 and chrna4 genes were re-expressed (using lentiviral vector) in the a6À/À VTA and a4À/À VTA (respectively), the reinforcement property of nicotine was restored. 145 This important study confirms that CHRNA6 and CHRNA4 (as well as CHRNB2) expression in the VTA is both necessary and sufficient for self-administration of nicotine. 145 Drenan et al. 132 used genetically manipulated a6-nicotine-hypersensitive mice (substitution of Leu with Ser on the 9 0 residue in the M2 domain) to show the role of this subunit in modulating DA transmission. The hypersensitive a6-mice showed increased DA neuron firing in the VTA compared with WT. Moreover, administration of a selective-a6 agonist stimulated greater striatal DA release in the mutated mice. On the behavioral level, KI animals were hyperactive both in the home cage and when introduced to a novel environment, consistent with increased DA release. 132 Taken together, these observation point to specific involvement of the a6* receptor in regulation of DA release.
CHRNA4
In addition to the role of the CHRNA4 subunit in the nicotine self-administration model of acute reinforcement described above, 145 involvement of the a4-nAChR subunit in nicotine-induced reward, tolerance, and sensitization was demonstrated in engineered mutant. 146 Single-point mutation in the poreforming M2 domain of the a4-subunit-encoding gene (Leu9 0 to Ala9 0 ) was introduced by the researchers. As a result, the a4-subunit containing receptors of this knock-in (KI) mouse became hypersensitive to nicotine. 146 At nicotine doses 50-fold less than that required in WT mice to elicit reinforcing (measured by CPP test) and reward behavior, the mutated
Leu9
0 Ala mice developed a significant place preference for nicotine. Knock-in mice were much more likely to develop tolerance compared with WT, assayed by nicotine-induced hypothermia with chronic nicotine infusion. 146 Similar to b2-KO mice, a4-KO exhibit striatal DA levels that do not increase in response to nicotine, supporting the notion that a4b2* nAChRs are necessary for DA release. 147 Morphological changes in nigrostriatal dopaminergic neurons in drug-naive adult a4(À/À)-mice have been described; KO mice had significantly larger terminal arbors than WT. 148 In addition, KO mice had impaired DA transporter levels and impairment in locomotor activity in response to DA agonist and antagonist. 148 The mouse strain dependent A529 polymorphism in the a4-subunit modulates nicotine intake among different strains. This functional polymorphism (alanine to threonine residue exchange at position 529, located in the second intracellular loop), which was shown to influence nicotine-induced 86 
Rb
þ efflux, plays a pivotal role in nicotine but not ethanol, consumption and preference. 149, 150 This effect most likely occurs through changes in the sensitivity of a4-containing nAChR to nicotine, possibly due to change of the ratio between high and low affinity a4b2*-receptors.
151
CHRNA7
Despite the widespread expression of a7-subunit containing receptors in the brain, studies in KO mice have not identified a role for this receptor in nicotine reward and conditioning. 77, 131 a7-KO studies have failed to support a role for this subunit in sensitivity to the behavioral effects of nicotine. a7À/À nicotinenaive mice do not display different IV self-administration of nicotine (model of acute reinforcement) than WT, 145 and a7-KO mice did not show weakened responses to nicotine in a drug discrimination experiment nor difference from WT in sensitivity to the locomotor depressant effects of nicotine. 152, 153 The development of nicotine tolerance did not differ between a7-KO and WT mice. 154 Somatic withdrawal signs (after intraperitoneal injection of nAChR antagonist to induce nicotinic withdrawal) are reduced in chrna7 KO mice relative to WT littermates. 155 However, other reports suggest that a7-subunit involvement in withdrawal is restricted to somatic signs and does not affect other withdrawal symptoms such as affective ones, 77, 143 whereas others do not support the role of this subunit in somatic withdrawal signs either. 156 This discrepancy may result from differences in treatment regimens and protocols. 155 Some caution is required in interpreting these results. The relative absence of nicotine-behavior phenotypes in a7-KO mice does not necessarily mean lack of a biological role for the a7-subunit in these phenotypes; such a role may be compensated by other nAChR subunits, such as a4 and b2.
Other receptors A relatively small number of studies have been reported in the literature regarding nicotine-related behaviors of other nAChR genetically manipulated mice. a3À/À mice suffer from high perinatal mortality which impairs research on nicotine effects in genetically manipulated mice totally lacking this subunit. Compared with WT, heterozygous a3 þ /À mice were partially resistant to nicotine-induced seizures but manifested normal sensitivity to the hypolocomotor effects of nicotine (possibly due to partial expression of this subunit in the heterozygous mice).
157 a5À/À mice lacking chrna5, the gene cluster neighbor of chrna3, reach adulthood and behave normally under basal conditions, but display lower sensitivity to short-term effects of nicotine than WT mice. 158 Resistance of a5À/À mice to nicotine was observed in a range of nicotine doses (both low and high doses), and affected seizure sensitivity as well as several other behavioral effects, especially those concerned with locomotor activity. Involvement of the a5-subunit in some physical aspects of nicotine withdrawal (but not affective nicotine withdrawal signs) has been reported. 143 Treatment of nicotine-dependent a5-KO mice with a nicotinic antagonist (mecamylamine) caused reduction in somatic signs compared with WT, whereas anxiety-related behavior was still present. a5-subunit containing receptors are found in the PNS (including ganglionic a5b4*-receptors), and may play a role in mediating these somatic withdrawal signs. 143 Molecular function of neuronal nAChRs in ND: pharmacological and biochemical aspects A wide range of neuropsychopharmacological data support the notion that ND involves more than one specific nicotinic receptor subtype (for recent comprehensive reviews see: Rose 16 ; Picciotto et al.).
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This supports our hypothesis that different variants in multiple neuronal nAChR subtypes may mediate genetic vulnerability to ND. The addiction process is complicated, and depends on many factors including pharmacological characteristics of the receptor such as differential affinity for nicotine, subunit composition and stoichiometry. 16 Three fundamental features of the cholinergic receptor system are discussed here briefly: differential receptor affinity for nicotine, receptor activationdesensitization cycle and nicotinic receptor upregulation after chronic nicotine exposure or withdrawal. These pharmacological traits have a crucial influence on ND-related behavior. As receptor desensitization (decreased response to agonist) and upregulation after chronic nicotine exposure (with potential for increased response to agonist) act in opposite directions, these mechanisms seem compensatory to each other. 159 So far only very limited research has been carried out regarding the possible influence of identified genetic variants in nAChR-encoding genes on these pharmacological traits. In the following section, we point out possible mechanism by which neuronal nAChR variants may influence the pharmacological profile of the subunits and of the receptor subtypes containing them.
General overview
Receptor desensitization. A well-documented characteristic of nAChRs is that they are reversibly desensitized when chronically exposed to an agonist. Desensitization is a temporary decrease or loss of the biological reaction of nAChRs after continuous or repetitive exposure to nicotinic agonist stimulation. 21, 34 In vitro electrophysiological measurements have shown that prolonged acetylcholine or nicotine application (in a time scale of minutes) produce a progressive decline of the currents carried by nAChRs. [160] [161] [162] Several models of desensitization have been proposed, suggesting that this process represents an allosteric protein behavior. 46 According to the classical Katz and Thesleff 163 model, nAChRs exist in three states: resting, activated and desensitized. Agonist binds to the resting receptor (usually with low-receptor affinity), and activates it. Then the receptor is desensitized (with high agonist affinity), and subsequently recovers. Recovery from desensitization is agonist independent.
164 Different nAChRs have different probabilities of desensitization in response to varying concentrations of nicotine. This fact may have significance for ND due to the changing concentrations of nicotine resulting from cigarette smoking throughout the day. 16 nAChR upregulation. After chronic nicotine exposure, high-affinity agonist binding to nicotinic receptors is increased (particularly the a4b2*-subtype) in both animal models and humans. This process is termed nicotine-induced upregulation 22, 165 and may be involved in the pathophysiology of ND. This striking effect of chronic nicotine exposure was shown in postmortem radioligand-binding studies performed in the brains of smokers and nonsmokers. An increase in [ Actually, nAChR upregulation has been reported in several different in vivo and in vitro systems, 21 after various nicotineexposure regimens and in many brain areas, such as the striatum, cortex, midbrain and hippocampus. 168 The mechanism of nAChR upregulation, probably involves increase in receptor number, rather than augmentation of receptor affinity for nicotine. 21, 169 Several mechanisms has been proposed to explain it, such as accelerated receptor transition from the endoplasmic reticulum to the surface membrane. 170 Genetic variation in multiple brain nAChRs and ND L Greenbaum and B Lerer nAChR activation-desensitization cycle and ND In considering the possible contribution of receptor activation and desensitization to the rewarding effect of nicotine in the brain, the attention of most researchers has traditionally focused on a4b2*-receptors, which comprise the majority of nicotinic receptor sites in the brain, and bind nicotine with high affinity. 18 However, the nicotine concentrations present throughout the day in the brains of smokers causes saturation and desensitization of these receptors at an early stage, and they are not available for nicotine action for most of the day. 16 Using the highly selective 2-FA radioligand enabling visualization of brain a4b2*-nAChRs with positron emission tomography in humans, Brody et al. 47 showed that daily smokers have nearly complete saturation of brain a4b2*-receptors throughout the day. Moreover, one to two puffs of a cigarette resulted in 50% occupancy of a4b2*-nAChRs for 3.1 h after smoking. Smoking a full cigarette (or more than one) resulted in more than 88% brain receptor occupancy, Thus, according to this neuroimaging study, 96-98% of a4b2*-nAChRs in the brains of nicotine-dependent smokers are occupied during the day. These findings show that in nicotine-dependent smokers, an almost complete shift of a4b2*-receptors to the high-affinity desensitization state takes place during the day. 47 According to Benowitz et al., 8 the nicotine concentration in the blood of chronic smokers during the day is in the range of 60-300 nM. As even low levels of nicotine exposure results in substantial occupancy and desensitization of brain a4b2*-nAChRs, it is plausible that high-affinity nicotine binding to a4b2*-receptors is not in itself a sufficient mechanism to explain continued smoking in nicotine-addicted individuals throughout the day. 16, 171 On the other hand, nAChRs with low affinity for nicotine are not susceptible to rapid saturation, and can continue functioning and responding throughout the day. Thus, selective desensitization of some nAChR subtypes, while maintaining the activity and functionality of others may play a significant role in ND. One important receptor subtype to consider in this context is a7, also widely expressed in the brain. a7*-containing receptors in the VTA/SNc are much less susceptible than a4b2* to desensitization at the daily blood and brain nicotine concentrations of smokers. 171 Up to 500 nM concentration of nicotine (beyond the nicotine concentration range of chronic smokers, as discussed above) causes very little desensitization of VTA/SNc a7*-nAChR currents. 171 As mentioned in Section 'nAChR subunits', DA release in the NAc is enhanced by glutamatergic excitatory drive from the laterodorsal tegmentum and pedunculopontine tegmentum. The glutamatergic afferents reaching VTA DA neurons express presynaptic a7* nicotinic receptors, which have a relatively low-nicotine affinity, and are not highly desensitized by the nicotine concentrations achieved by smokers. 9 So, while nicotine concentrations are elevated and a4b2* receptor desensitized, a7* receptors on glutamatergic afferents remain active and enhance glutamate excitation of the DA neurons.
It is neurobiologically reasonable that genetic variants in a4b2* and a7* nAChRs may directly and indirectly influence the affinity of the receptor containing the subunit for ligand activation-desensitization cycle and/or other pharmacological traits of interest. Hutchison et al.
112 assessed the influence of the CHRNA4 3 0 UTR SNP, rs22236196, on a4b2 binding in human postmortem brain tissue. Individuals carrying the TC genotype for this SNP showed greater binding in the NAc than carriers of the TT genotype. 112 Bierut et al. 88 studied the influence of the amino acid change caused by CHRNA5 rs16969968 on the maximal response to nicotinic agonist. They found that a4b2a5 receptors with the aspartic acid variants (D398) had more than two times greater maximal response to nicotine than a4b2a5 receptors with asparagine. 88 The implication is that the decreased nAChR function is associated with the increased risk for ND. However, there were no differences in expression pattern between the two isoforms. 88 Mao et al. 172 estimated that (a4b2) 2 a5 receptors constitute 11-37% of the total a4b2* nAChR population, depending on the brain region. Accordingly, the potential influence of the a4b2a5N398/a4b2a5D398 variant on total brain a4b2* receptor response to nicotine is probably substantial.
Other genetic variants in the CHRNA5-CHRNA3-CHRNB4 cluster associated with ND phenotypes may also have functional role due to influence on receptor response to nicotine, ligand affinity and activationdesensitization cycle. As discussed in the Section 'Pharmacological properties of neuronal nAChRs and their involvement in human disorders', b4-expression in the VTA is low, but b4-containing receptors are found in the habenula, locus coeruleus, IPN and cerebellum. 58, 71, 173 a3b4* have lower-binding affinity than do a4b2* receptors in transfected cells, 174 they do not become fully occupied and saturated at the nicotine concentration range detected in smokers' plasma during the day, 16 and are more resistant to rapid desensitization than are a4b2* receptors. 175 Taking receptor affinity, saturation and differential desensitization considerations into account, Rose 16 suggested that b4-subunit containing receptors contribute to the reinforcing effect of nicotine. Further research on the pharmacological importance of NDassociated variants (or variants tagged by them) in the CHRNA5-CHRNA3-CHRNB4 cluster is clearly warranted.
Multiple nAChR upregulation and ND a4b2* receptor upregulation: possible contribution to ND and withdrawal. Buisson and Bertrand 169 reported that human a4b2 nAChRs expressed in HEK-293 cells are upregulated after chronic nicotine exposure, with an increase of up to 70% of the high affinity receptor fraction. Several in vivo imaging studies of a4b2* receptor upregulation have been performed in humans, using highly selective radioligands combined with positron emission tomography scans. Wullner et al.
176 used 2-FApositron emission tomography to evaluate a4b2 nAChRs in smokers and nonsmokers. The total brain distribution volume of the radioligand in vivo was significantly increased in the brains of smokers, especially in the cerebellum and brainstem. Staley et al. 177 imaged b2* nAChRs in human smokers using [ 123 I]5-IA SPECT, and compared receptor availability during early abstinence with corresponding values in nonsmokers. As expected, the densities of brain b2* nAChR were higher in the striatum, cerebellum and cerebral cortex of smokers during early abstinence, compared with nonsmokers. Moreover, there was a correlation between somatosensory cortex b2* nAChR availability and the urge to smoke. 177 Upregulation following smoking cessation is time dependent, and 3 weeks later nAChRs were downregulated to the levels of nonsmokers. 178 The possible contribution of nAChR upregulation to the pathophysiology of ND is not fully understood, but is believed to be mediated by midbrain DA release. Vezina et al. 168 have proposed that nicotine exposure produces temporary nAChR upregulation, leading to augmentation of midbrain dopaminergic neuron excitation and the induction of long-term potentiation.
Another hypothesis regarding the role of upregulation in ND is that upregulation is a compensatory response of the cholinergic system following desensitization of neuronal nAChRs after chronic nicotine exposure. 159, 161 The increase in receptor number enables the cholinergic system to counteract the chronic deficits caused by the initial rapid desensitization due to chronic agonist exposure. 179 The increase in nAChR number may be the underlying mechanism of nicotine tolerance and ND. 21 As explained in the Section 'nAChR upregulation', the upregulation process seems to result from an increase in a4b2* receptor numbers expressed on the membrane, although the exact mechanism is not yet clear. 159 Genetic variants within these two subunits may influence upregulation processes; of special importance are variants in the UTRs of the genes (such as CHRNB2 3 0 UTR rs2072660 and rs2072661or CHRNA4 3 0 UTR rs2236196) and promoters, which have a regulatory role in gene expression. For example, as described in Section 'CHRNA4', the CHRNA4 5 0 promoter rs6122429 and CHRNA4 3 0 UTR rs2236196 affect luciferase construct activity, a marker of gene expression. 112 In the construct containing the G-allele, expression was fivefold greater than the A-allele construct. 112 Different baseline levels of gene and protein expression, as a result of genetic variants in regulatory regions, may have a profound impact on the upregulation potential of receptors after nicotine exposure. To our knowledge, no correlation has been sought between specific SNPs and upregulation patterns, either in cell cultures or in vivo. In humans, evaluation of the relevance of SNPS to upregulation can be studied in postmortem brain tissue from smokers but also in living volunteers using positron emission tomography and SPECT radioligands.
Upregulation of non-a4b2*-subunit containing receptors. Recent studies show that not only a4b2-containing receptors, but also other neuronal nAChR are upregulated after nicotine exposure. The subunit patterns of upregulation differ from one another in terms of time course and required nicotine concentration. 165 In vitro studies in cells transfected with homomeric a7 and various heteromeric a3b2, a6b2 and a3b4 receptors show upregulation induced by nicotine, but data from in vivo studies is more variable and complex. 26 Upregulation of a7-subunit containing nAChRs after chronic nicotine treatment has been reported in several brain regions of the mouse, including striatum, midbrain and cortex. 180, 181 Upregulation of human a7-subunits was shown in human embryonic kidney (HEK) cells after chronic exposure to nicotine and other receptor ligands. 182 Data on a6* receptors upregulation is less clear. On the one hand, some in vivo reports support upregulation of a6-containing receptors in rats during long-term self-administration of nicotine. 183 Although substantially higher nicotine concentrations are required to upregulate a6b2 and a3b2 receptors compared with the a4b2* receptor, this high level of nicotine may be reached during the fast fluctuation of nicotine in smokers' serum, immediately after smoking a cigarette. This implies that different phases of nicotine intake during the day involve different receptor subtypes upregulation. 165 On the other hand, other papers describe no change or even downregulation of this subunit. McCallum et al. 184 did not observe upregulation of striatal a3*/ a6* receptor subunits, possible due to differences in nicotine exposure regimens and concentrations. Perry et al. 185 reported downregulation of a6* receptors number and function in the striatum.
The a6-and b3-subunit upregulation is of special interest because these subunits are expressed in midbrain DA neurons, and modulate DA release. 186, 187 It is possible that some regulatory variants within the CHRNA6-CHRNB3 gene cluster are associated with upregulation and others with downregulation of the subunits.
As mentioned in the Section 'nAChR activationdesensitization cycle and ND', (a4b2) 2 a5 receptors constitute 11-37% of the total a4b2* nAChRs. 172 However, while a4b2* nAChR upregulate after chronic nicotine administration, it seems that the particular (a4b2) 2 a5 subtype does not. (a4b2) 2 a5 resistance to nicotine-induced upregulation probably has implications for the mechanism of ND, due to the suggested contribution of a4b2* nAChR upregulation to ND. 172 As mentioned, a5 is an accessory subunit, and some of the variants described in the CHRNA5-CHRNA3-CHRNB4 cluster may be involved in the upregulation resistance mechanisms.
Finally, important reservations should be noted regarding non-a4b2 subtype upregulation. Consistently, higher nicotine levels are required for upregulation of these receptors compared with the a4b2* subtype. These higher concentrations differ from the physiological accumulation of nicotine levels in smokers' serum and brain, which rises slowly and is relatively sustained during the day, after hours of continued smoking. 21, 165 Further study is warranted to determine the functional role of upregulation in the addiction process in humans, and the possible influence of genetic variants within nAChRs genes on it.
nAChR genes, personality traits, neurocognition and ND Although genetic factors play a significant role in NDrelated behavior, other factors such as demographic and family background, psychopathology, life experience, personality traits and cognitive function are pivotally involved in this complex trait whether directly or interactively. 81, 188, 189 Before dependence on nicotine is established, factors such as these (as well as genetic factors) influence the likelihood of initiating smoking (SI) which is a prerequisite for ND to develop. A further complexity that must be taken into account is that personality, psychopathology and cognitive function are themselves influenced by genetic factors. 190, 191 It is thus clear that complex models are required to effectively study the role of genes and environment in ND-related behaviors. A comprehensive evaluation of this subject is beyond the scope of this review. However, we will address general concepts that are important and findings that illustrate the concepts, as summarized in Supplementary Table 2 .
It is well established that the tobacco use is associated with personality traits such as neuroticism, impulsivity, extraversion, novelty seeking, harm avoidance and antisociality. [192] [193] [194] [195] Given the well-established role of genetics in personality there is growing interest in identifying specific genetic variants that may be implicated in personality traits. 190, 196 An early, much studied and highly debated finding is the association of novelty seeking, with a functional variant in the DA D4 receptor gene. 197, 198 Similar findings have implicated genetic variants in personality traits such as harm avoidance 199 and neuroticism. 200 Thus, although genetic variants may influence ND directly, they may also do so through their influence on personality traits that are related to cigarette smoking and use of other substances. 191, 201 For example, interaction between functional variants in the promoter of the serotonin receptor gene (5-HTTLPR-L/5-HTTLPR-S) and neuroticism was found to influence smoking behavior. 202, 203 Identifying the genetic contribution of nAChRencoding genes to personality traits could shed further light on the complex interaction between genes, environment and personality factors in smoking behavior. In a study of serotonergic candidate genes in our sample of young Israeli women, 204 SNPs in five serotonin receptor genes (HTR1A, HTR1B, HTR2A, HTR2C and HTR6) and the 5-HT transporterlinked polymorphic region (5-HTTLPR) were genotyped. In a logistic regression model for SI, the personality trait, novelty seeking was a significant risk factor. A five SNP CACCC haplotype in HTR6 was a strong protective factor against SI (OR = 0.26; P = 0.007). The interaction of HTR6-C276T genotype and lifetime traumatic experience contributed strongly to the risk of SI (OR = 13.88, P = 0.0001). Similar results were obtained for ND in a study of dopaminergic candidate genes in the same sample of young Israeli women. 205 Novelty seeking was a risk factor (OR = 1.07, P = 0.03); the DAT1_E15274-DAT1_VNTR G-9 haplotype (OR = 0.37, P = 0.001) and the interaction between trauma and a DAT1_E15274-DAT1_VNTR C-9 haplotype (OR = 0.15, P = 0.01) were protective. 205 A potential interaction between nAChR-encoding genes and cognitive function in susceptibility to ND is of great interest because of earlier reports on the effect of nicotine on cognitive processes and the association of cigarette smoking with specific cognitive attributes. 206, 207 It has been suggested that smoking may be used as a form of self-medication by some individuals because of beneficial acute effects on cognitive functioning, mainly in the attention domain. 208, 209 A large body of evidence supports the involvement of neuronal nAChRs in cognitive functions. For example, selective-a7 agonists show efficacy in learning and memory tasks in animals 40 and a role of the a4b2-subunit in cognition is supported by KO and antagonist studies. 20 Thus, genetic variations in nAChRs that influence neurocognitive functions may affect smoking behavior through this mediation, as discussed above for personality traits.
Attention, impulsivity, nAChRs and susceptibility to ND Attention deficit/hyperactivity disorder (ADHD) is characterized by attentional, hyperactive and impulsivity symptom clusters that manifest as cognitive deficits on tests of attention and executive function. 20 .
Epidemiological reports show a high prevalence of smoking among individuals diagnosed with ADHD compared with nonsmokers. According to Lambert et al.,
210 46% of adolescents with ADHD were daily smokers by the age of 17 years compared with 24% of age-matched controls. The finding continues into adulthood, the figures being 35 vs 16%, respectively. 210 Accumulating evidence suggests that cholinergic system dysregulation contributes to the pathophysiology of ADHD, based on animal, pharmacological and imaging studies. 20, 211, 212 215 and rs3787141. 211 Some of these findings were not replicated by other groups (for example, Bobb et al. 216 ). Although inconsistent, the findings can be interpreted as supporting involvement of the CHRNA4 gene in ADHD. Impulsivity, a central feature of ADHD, is a recognized personality trait associated with smoking behavior. 193, 194 Thus, genetic variants in CHRNA4 may contribute to NDrelated behavior both directly and as risk factors for ADHD. Interestingly, the synonymous CHRNA4 SNP RS1044396 was found to be associated with interindividual differences in visuospatial attention. 217 Furthermore, although not modulating working memory by itself, this variant was involved in the interaction of attention and working memory. 218 Recent work by our group suggests that young women who smoke have a neurocognitive profile that is characterized by small but significant impairments of sustained attention and response inhibition. 209 We suggest that the improvement by nicotine of cognitive function in these domains may predispose young women who initiate cigarette smoking to maintain the habit. 209 Subsequently, Rigbi et al. 189 showed that the performance on the relevant test measures (for example, response inhibition) is modified by specific variants in nAChR genes, mostly in CHRNA4, CHRNA7 and CHRNB3 but also in other nAChR genes. 189 nAChR genes, neuroticism and ND A connection between neuroticism and smoking is well established, both in adults and adolescents. 188, 194, 219 Neuroticism is associated with manifestations of anxiety and depression. 220 Goodwin and Hamilton 201 suggested a connection between cigarette smoking, panic attacks and neuroticism. In the genetic context, as discussed above, the serotonin transporter polymorphism has been reported to interact with neuroticism, to influence several NDrelated phenotypes. 202, 203 Nicotinic cholinergic receptors modulate the release of neurotransmitters that have critical roles in the regulation of anxiety (DA and serotonin). 18 In humans, according to smokers' accounts, smoking may have anxiolytic effects, which are likely attributable to the nicotine contained in cigarettes. 221 Taking into account the psychological characteristics and genetic variants, controlling for the background variables and using a best-fitting logistic regression model of SI, Greenbaum et al. 81 found that a 5 SNP haplotypes in CHRNB2, neuroticism and novelty seeking were significantly associated with SI (P = 5.9 Â 10 À14 , Nagelkerke r 2 = 0.30). The model to predict high ND as compared with low ND (P = 2.24 Â 10
À7
, Nagelkerke r 2 = 0.40), included two SNPs in CHRNA7 (rs1909884 and rs883473), one in CHRNA5 (rs680244) and the interaction of CHRNA7 SNP rs2337980 with neuroticism, although neuroticism was not significant in itself. It is of interest that Greenbaum et al. 81 found a strong contribution of background and psychological factors to SI with a relatively small contribution of variations in nAChRs genes. On the other hand, the contribution of background and psychological characteristics to severity of ND was smaller but that of nAChR genetic variants larger. 81 Further support for the influence of nAChRs on neuroticism comes from genetically manipulated mice. The behavior of b4À/À mice differs from WT (b4 þ / þ ) littermates, when examined on behavioral test related to anxiety.
70 b4-KO mice showed increased exploratory behavior and increased climbing activity, 70 interpreted as decreased anxiety-like behavior. Taken together, these findings point to the possibility that CHRNB4 involvement in ND is at least partially mediated by the effect of this nAChR subunit on anxiety. In another relevant study, point mutation of a single amino acid in the a4-subunit M2 transmembrane region (leucine-to-serine) generated nicotine hypersensitive a4-receptors. 222 These mice displayed increased level of anxiety (mostly in the elevated plus maze), as well as other characteristic such as poor motor learning and excessive locomotion activity, that was eliminated by low doses of nicotine injection. 222 The role of the a4-subunit in anxiety in a stressful setting was assessed by Ross et al.
223 a4-KO mice show behavioral features consistent with heightened basal levels of anxiety and increased exploratory activity in stressful settings, 223 consistent with the reports of Labarca et al. 222 Finally, as with deletion of the a4 and b4-subunit, chrnb3 KO mice showed altered anxiety-like behavior, when compared with WT, assessed by a series of behavioral tests. 224 Thus, in addition to their direct influence on NDrelated phenotypes, neuronal nAChRs genes may mediate predisposition to neuroticism, a personality trait that is a susceptibility factor for smoking.
Conclusions
In this review, we have surveyed several lines of evidence that support the involvement of genetic variation in different neuronal nAChRs subunits in ND. Findings from three genetic research approaches (linkage analysis, candidate-gene association studies and GWAS) analyzing various ND phenotypes with different assessment tools support the involvement of several nAChR genes in ND. By far, the strongest and most compelling evidence is for association of CHRNA5-CHRNA3-CHRNB4 gene cluster variants with several ND-related phenotypes, as studied extensively in the last 2 years. Mouse models with genetic manipulation of nAChR genes display behavioral phenotypes related to ND, show the role of the cholinergic system in regulating dopaminergic transmission and provide a major tool to evaluate the contribution of each subunit to ND susceptibility. Pharmacological and biochemical properties of receptor subunits, such as affinity for nicotine, desensitization and receptor upregulation, differ among subtypes and functionally relevant genetic variation in these receptors is likely to play a role in differential susceptibility to ND. Various nicotinic receptors are expressed on mesolimbic DA neurons and are believed to modulate the reinforcing properties of nicotine. Finally, neuronal nAChRs variants are associated with personality traits (such as neuroticism and impulsivity) and neurocognitive functions, which may contribute to ND. Taken together, these data suggest that genetic susceptibility to ND is linked to several nAChR subtype genes and variants in each subunit gene may have independent as well as interactive contributions to ND at the molecular level.
On the basis of previous neurobiological and pharmacological knowledge, CHRNA4 and CHRNB2 are highly plausible candidate genes for ND. a4b2* receptors are widely expressed in the brain and bind nicotine with high affinity.
22 a4b2* nAChRs are upregulated in the brains of smokers. 166 A partial agonist of this receptor, varenicline, is a newly approved smoking cessation drug. However, continued nicotine consumption during the day by heavy smokers is difficult to explain, due to the rapid saturation and desensitization of the receptor. 16 Studies in genetically manipulated mice clearly point to an essential role of both genes in ND (especially positive reinforcement), although reports are somewhat more impressive for CHRNB2 than CHRNA4. However, genetic finding do not correlate with the central pharmacological role of these two subunits. Modest support for the involvement of the CHRNA4 gene in ND is provided by relatively small candidategene association studies and linkage studies, but not by large scale GWASs (See Table 3 ). For the CHRNB2 gene, most candidate-gene studies fail to show association with ND-related phenotypes. This surprising contrast between solid, well-established neurobiological knowledge of ND mechanisms, receptor pharmacological traits (high nicotine binding and upregulation) and hypothesis supporting experiments in mouse models on the one hand, and modest genetic findings as well as rapid receptor saturation and desensitization on the other, supports the notion of a potential contribution of genetic variation in additional neuronal nAChR subtypes to ND susceptibility.
The findings regarding CHRNA7 are somewhat similar. As for CHRNA4 and CHRNB2, neurobiological and pharmacological data support a major involvement in ND. This receptor is expressed in most CNS regions, including VTA and striatum. It binds nicotine with low affinity, is not desensitized in the brains of smokers during the day (in contrast to a4b2*), 171 and upregulates after chronic nicotine administration. 225 However, both genetic findings and experiments in mouse models do not support a substantial link to ND. Furthermore, a7-KO mice do not display ND-related behavior, with the exception of some aspects of nicotine withdrawal symptoms (although these surprising findings may be explained by compensation of other subunits). However, relatively modest data support the contribution of these three genes to ND relevant personality traits, such as impulsivity (CHRNA4,) neuroticism (CHRNB2, CHRNA7) and to neurocognitive function (CHRNA4, CHRNA7).
Possible missing links
We suggest that the a3, a5-6 and b3-4 nAChR subunitencoding genes play a much more pivotal role in ND than hitherto appreciated and that functional, most likely regulatory variants within them may contribute differentially to ND-related behavior (see Table 5 ). Although neurobiological knowledge of the physiological role of the receptors containing these subunits in ND is relatively limited compared with available data regarding a4b2* and a7* receptors, recent reports support their critical role as modulators and accessory subunits in nAChRs. Moreover, impressive, robust genetic associations with ND phenotypes have been reported. As neurobiological research advances, the complexity of nAChR composition is increasingly recognized. In fact, the number of neurobiologically relevant receptor subtypes (with distinct biophysical and pharmacological properties) is larger than that estimated previously. 18 For example, current knowledge indicates that DA nerve terminals in the striatum express as many as five different nAChR subtypes: a4b2, a4a5b2, a4a6b2b3, a6b2b3 and a6b2. 226 This functional diversity of nAChR receptors in terms of composition and role is highly influenced by the a3, a5-6 and b3-4 receptor subunits, not paid much of attention until recently ( Table 6) .
As presented in Table 3 , there is considerable support for the association of the CHRNA5-CHRNA3-CHRNB4 gene cluster with ND, based on GWAS and case-control study results, mainly from EA samples, encompassing thousands of participants and using several measures of ND. Particularly convincing associations have been reported for the non-synonymous, CHRNA5 exon 6 SNP, rs16969968, and the CHRNA3 exon 5 SNP, rs1051730. Another variant, not correlated to the above two SNPs, the CHRNA3 3 0 UTR SNP, rs578776, is independently associated with ND. The fact that 'hypothesis-free' findings of GWAS and the biologically plausible, candidate-gene approach converge in this case is striking.
The accessory a5-subunit modulates biophysical and pharmacological properties of nAChRs (like calcium permeability or desensitization rate). 27, 172, 227, 228 Indeed, variation in rs16969968 influences the maximal response of a4b2a5 receptors to nicotine. 88 Although a5-KO mice are viable, so far only limited research on ND-related features has been reported, including that mutant mice are less sensitive to nicotine-induced seizure and locomotor activity 158, 229 than WT, and show a reduction in physical withdrawal symptoms 143 (See Table 4 ).
The nearby a3-gene, located within a very high LD block, is also expressed in VTA and other ND relevant brain regions, and this receptor subtype is upregulated after nicotine exposure.
165 a3b4* receptors have lower binding affinity than a4b2* receptors in transfected cells. 174 Unfortunately, homozygous a3-KO mice are not viable, complicating the assessment of the involvement of this receptor subtype in ND.
Knockout mice for CHRNB4, the third member of this gene cluster, mainly show alternations in withdrawal symptoms, and anxiety-like behavior, 72 correlating with the high expression of this receptor in the PNS. This may suggest CHRNB4 involvement in neuroticism, a personality trait related to ND. The b4-subunit does not become saturated at the levels of nicotine found in smokers blood 16 and is less susceptible than a4b2* receptors to the process of rapid desensitization. 175 The CHRNA6-CHRNB3 gene cluster, is, in our view an important candidate for ND susceptibility. a6-and b3-subunits colocalize in DA neurons, and both are expressed in the VTA. b3 (such as a5) is an auxiliary subunit, assembles with other neuronal nAChR a-and b-subunits, and is important for the correct assembly, stability and transport of a6* nAChRs in dopaminergic neurons. 26, 32 Another nAChRs sub-population, a6b2* receptors, are located in the striatum, and mediate DA release. 64 Interestingly, both a6-and b3-subunits are present in a4a6b2b3 receptors on dopaminergic neurons in the striatum and NAc. According to some papers, this receptor is characterized by possessing the highest affinity for nicotine among all nicotinic receptor subtypes reported until now, and may play an important role in regulating DA-related behaviors, rendering it relevant to the reinforcing effects of 
' þ ' -no or little evidence support possible involvement in contribution to ND-related phenotypes. ' þ þ ' -medium support for possible involvement in contribution to ND-related phenotypes. ' þ þ þ ' -convincing evidence for possible involvement in contribution to ND-related phenotypes.
nicotine. 30, 132, 226 Genetic support for the involvement of the CHRNA6-CHRNB3 cluster in ND has been reported in one GWAS and a large (B300) candidategene association study on the same sample, 76, 78 and by several other candidate-gene studies analyzing ND and other smoking-related phenotypes. 90, 108, 109 Data from KO mice are supplementary: chrna6 KO nicotine-naive mice do not display self-administration of nicotine (in contrast to WT), but when the chrna6 gene is re-expressed in the a6À/À VTA, the reinforcement property of nicotine is restored. 145 KI mice model of hypersensitive a6-receptor shows increased DA neurons firing in VTA, an hyperactive behavior, compared with WT.
132 b3-KO mice show altered DA release in the striatum after nicotine stimulation, altered locomotor activity and prepulse inhibition of acoustic startle response. 68 Pivotal issues for future research The data presented here support our hypothesis that multiple neuronal nAChR subunits contribute to genetic susceptibility to ND. However, many questions are still open, and much research is required to at least partially answer some of them. Future research should encompass all nAChRs and assess the independent and interactive role of each subunit in ND-related phenotypes. Ultimately, the full 'catalog' of ND genes may contain all the neuronal nAChRs-encoding genes, each responsible for a particular intermediate phenotype (reinforcement, withdrawal, tolerance, sensitization and so on). Gene-gene interactions may also be important, and it is possible that the genetic contribution of some nAChRs to ND may mainly be as 'modifier genes', mediating the genetic contribution of other nAChR genes, as well as non-nAChR genes. To achieve these goals, uniform definitions of ND-related phenotypes are required. As shown in Table 2 , the variable definitions currently used by different research groups complicate replication studies and lead to inconsistent results.
Some nAChR-encoding genes, especially the CHRNA5-CHRNA3-CHRNB4 gene cluster, were found to be associated not only with ND but also with addiction to additional substances of abuse such as alcohol and cocaine. 94, 97 These findings suggest the existence of a general pathophysiological role for nAChRs in addiction behavior. Other subunit genes should be similarly assessed.
Further research is also required to understand the functional role of variants associated with ND. Two pivotal studies have been reported so far revealing an effect of the CHRNA5 SNP, rs16969968, on maximal receptor response to nicotine, 88 and the CHRNA4 3 0 UTR SNP, rs2236196, on expression of the gene and on a4b2 binding in postmortem brain tissue.
112
Further studies at the neurobiological level on other SNPs that have been associated with ND is essential, not only in terms of gene and protein expression but also in the context of influence on receptor ligandbinding affinity, activation-desensitization cycle and upregulation. As mentioned in Section 'a4b2* receptor upregulation: possible contribution to ND and withdrawal', combining neuroimaging and genetic approaches for evaluating these aspects should be fruitful. Three independent GWASs have reported association of the CHRNA5-CHRNA3-CHRNB4 cluster with LC. 80, 100, 101 Some of these studies suggest that this gene cluster does not confer susceptibility to LC by an effect on susceptibility to ND but directly, 100, 101 although another does support this mechanism for LC and peripheral vascular disease. 80 Functional studies of the significantly associated SNPs in nonneuronal tissues (lungs and peripheral arteries) are a high priority.
The contribution of particular SNPs to some aspects of ND can be evaluated in humans by assessing behavioral sensitivity to nicotine, as has been carried out by a few groups. 108, 112, 115 At the level of animal models, much behavioral research has been carried out on KO mice, mostly CHRNA4, CHRNA7, CHRNB2 and CHRNB4. Further studies of CHRNA2-3, CHRNA5-6 and CHRNB3 genetically modified mouse models are required. KI mouse models of some interesting SNPs (such as rs16969968) should be created and analyzed.
In conclusion, ND is a complex trait that involves not only genetic factors, but also demographic and familial factors, life experience, personality traits and neurocognitive factors. The design of future studies and sample recruitment protocols should take this into consideration, and assess at these factors. Models predicting ND-related behavior should include these variables in addition to genetic ones. Moreover, the direct contribution of variants within nAChR genes to personality traits (such as neuroticism and impulsivity) and neurocognitive function associated with ND should be studied separately. The answers to these and many other open questions will be achieved by using a multidisciplinary approach that combines genetics, pharmacology, biochemistry, psychology and genetically manipulated animal models. The importance of such efforts for smoking prevention and for the development of new treatments for smoking cessation is obvious. Nevertheless, it should be noted that the research in the field of ND should not be limited to nAChR genes; other promising candidate genes exist and others will no doubt emerge.
